tegafur has been researched along with Breast Cancer in 304 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase II study evaluated the efficacy and safety of anastrozole concurrent with tegafur/uracil (UFT) as neoadjuvant therapy for ER-positive postmenopausal breast cancer." | 9.27 | Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). ( Aono, T; Ito, T; Kagimura, T; Masuda, N; Matsunami, N; Miyoshi, Y; Nakayama, T; Noguchi, S; Sagara, Y; Taguchi, T; Takashima, T, 2018) |
| "We investigated the efficacy and safety of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium (TS-1) in patients with metastatic and recurrent breast cancer (MRBC), and the association between irinotecan metabolizing enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms and adverse events." | 9.20 | Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. ( Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U, 2015) |
| "We conducted a phase I study of a weekly nab-paclitaxel and S-1 combination therapy in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer." | 9.20 | Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer. ( Aruga, T; Iwasa, T; Komoike, Y; Kuroi, K; Makimura, C; Miyazaki, M; Nakagawa, K; Nishina, S; Okamoto, K; Saeki, T; Shigekawa, T; Tanizaki, J; Tsurutani, J; Yamashita, T, 2015) |
| "Capecitabine and S-1 are orally administered fluorinated pyrimidines with high-level activity against metastatic breast cancer (MBC)." | 9.20 | Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial. ( Ariyoshi, K; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Nagumo, Y; Odagiri, H; Sueoka, N; Teramoto, S; Tsubota, Y; Yamaguchi, T; Yamamoto, C; Yamamoto, D, 2015) |
| "A prospective randomized clinical trial was conducted to evaluate the efficacy of tamoxifen plus doxorubicin and cyclophosphamide compared to tamoxifen plus tegafur-uracil as an adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC)." | 9.19 | Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404. ( Ando, J; Aogi, K; Fukuda, H; Fukutomi, T; Inoue, K; Iwata, H; Kinoshita, T; Nakamura, K; Shibata, T; Shien, T; Takashima, S, 2014) |
| "This Phase II trial investigated the combination paclitaxel (P) and uracil-tegafur (UFT) in patients with metastatic breast cancer (MBC)." | 9.15 | Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial. ( Bazan, F; Chaigneau, L; Demarchi, M; Dufresne, A; N'guyen, T; Pivot, X; Stein, U; Thierry Vuillemin, A; Villanueva, C, 2011) |
| "To assess the efficacy and safety profile of biweekly vinorelbine and tegafur/uracil (UFT) as treatment in patients with metastatic breast cancer previously treated with anthracyclines and taxanes." | 9.15 | Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000-02 phase II study. ( Antón, A; Barnadas, A; Florián, J; Gayo, J; González-Quintás, A; Lao, J; Lomas, M; Margelí, M; Paules, AB; Ramos, M; Ribelles, N, 2011) |
| "The primary aim of this study was to compare the effectiveness of oral uracil-tegafur (UFT) with that of classical cyclophosphamide, methotrexate, and fluorouracil (CMF) given as postoperative adjuvant treatment to women with node-negative, high-risk breast cancer." | 9.14 | Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. ( Iwata, H; Kitaya, T; Kohno, N; Nakagami, K; Ohashi, Y; Sakamoto, G; Sano, M; Shimozuma, K; Sonoo, H; Takashima, S; Tokuda, Y; Tsuda, H; Watanabe, T; Yoshimoto, M, 2009) |
| " Therefore, we compared UFT with a combination therapy of cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients who had undergone curative surgery for axillary lymph node-positive breast cancer." | 9.14 | Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study. ( Asaga, T; Higaki, K; Inaji, H; Ito, T; Koh, J; Kohno, N; Komichi, H; Koyama, H; Kyono, S; Mitsuyama, S; Nishikawa, H; Ogita, M; Okamura, K; Osaki, A; Park, Y; Saito, T; Suzuki, T; Tanaka, F; Yamazaki, K, 2009) |
| "Two randomized clinical studies comparing the efficacy of oral UFT (2 years) with that of classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) (six courses) have been conducted in patients with resected early breast cancer." | 9.14 | Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial). ( Inaji, H; Koyama, H; Ohashi, Y; Sano, M; Suzuki, T; Watanabe, T, 2010) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 9.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "This article reports the results of a pooled analysis of six randomized trials conducted to study the efficacy of uracil and tegafur (UFT) in the adjuvant treatment of node-negative breast cancer patients." | 9.11 | Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. ( Abe, O; Abe, R; Akazawa, K; Koyama, H; Miura, S; Noguchi, S; Sugimachi, K; Uchino, J, 2005) |
| "A prospective randomized multi-center study was undertaken for 2 years and 3 months from November 1982, with the aim of examining the significance of using a combination of futraful (FT) and tamoxifen (TAM) for postoperative adjuvant therapy for stage II breast cancer after curative surgery." | 9.10 | Ten-year results of a randomized trial on adjuvant chemo-endocrine therapy with tamoxifen for stage II breast cancer. ( Asaishi, K; Hata, Y; Hirata, K; Kato, H; Okazaki, M; Okushiba, S; Takahashi, H; Todo, S; Uchino, J, 2003) |
| "To determine the maximum tolerated doses, toxicities, and therapeutic effect of an oral chemotherapy regimen consisting of uracil-ftorafur, etoposide, and leucovorin for metastatic breast cancer." | 9.10 | Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. ( Carlson, RW; Grekowicz, A; Hartman, AR; Lum, BL; Schurman, C; Shapiro, R; Sikic, BI; Stockdale, FE, 2003) |
| "This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer." | 9.09 | Paclitaxel, UFT, and calcium folinate in metastatic breast cancer. ( Blanke, C; Cohen, A; Dickson, NR; Hande, K; Johnson, D; Nicholson, BP, 1999) |
| "This phase I study was designed to determine the maximum tolerated dose (MTD) and dose-limiting side effects of combination treatment with paclitaxel (Taxol) and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral calcium folinate (Orzel) for advanced metastatic breast cancer." | 9.09 | Paclitaxel and UFT plus oral calcium folinate in pretreated metastatic breast cancer. ( Benner, S; Borquez, D; Harstrick, A; Klaassen, U; Lang, S; Oberhoff, C; Seeber, S, 1999) |
| "Paclitaxel (Taxol) is one of the most active drugs in the treatment of ovarian and breast cancers." | 9.09 | UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer. ( Dethling, J; Kühnle, H; Lück, HJ; Scholz, U, 1999) |
| "A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive primary breast cancer." | 9.09 | UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group. ( Asaishi, K; Hata, Y; Hirata, K; Kubo, Y; Mito, M; Ogita, M; Tanabe, T; Uchino, J, 1999) |
| "Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation." | 9.09 | Uracil/tegafur plus oral calcium folinate in advanced breast cancer. ( Alvarez, AM; Bonamasa, M; Bruno, M; Coppola, F; Cuevas, MA; Elli, A; Fein, L; Jovtis, S; Lerzo, G; Mickiewicz, E; Pedraza, C; Richardet, E; Suarez, LA; Uranga, G; Ventriglia, M, 1999) |
| "Thirty patients with pretreated advanced breast cancer were enrolled in a study aimed to establish the maximum tolerated dose and to evaluate the efficacy of oral idarubicin (12 mg/m2/day for 3 days every 4 weeks) with tegafur and levo-folinate (200 mg/m2/day and 50 mg/day, respectively, for a minimum of 6 days, increasing the dose and duration according to a modified Fibonacci scheme)." | 9.09 | Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancer. ( Cilenti, G; Lelli, G; Suriano, A; Tartarone, A; Tozzi, L, 1999) |
| " Moreover, combination therapy with paclitaxel and fluorouracil (5-FU) exhibits high activity in anthracycline-pretreated breast cancer patients: recent studies report response rates of 54% to 69%." | 9.09 | A phase I study. UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer. ( Canzler, U; Kühnle, H; Lück, HJ; Robner, D; Scholz, U, 2000) |
| "This article describes the design and early results of an open-label, nonrandomized phase I/II trial of oral UFT plus leucovorin therapy in combination with bolus injections of epirubicin and cyclophosphamide in patients with advanced or metastatic breast cancer." | 9.09 | UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer. ( Gregory, RK; Johnston, SR; Miles, D; Smith, IE, 2000) |
| "Thirty-four patients with metastatic breast cancer (MBC) who had progression of disease after high-dose chemotherapy (HDCT) with peripheral blood progenitor cell support (PBPC) had methotrexate, uracil and tegafur (UFT), and leucovorin (MUL) therapy administered: methotrexate administered intramuscularly in combination with UFT given orally and leucovorin given orally." | 9.09 | Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: a phase II study. ( Casado, A; Diaz-Rubio, E; Garcia-Carbonero, I; Garcia-Saenz, JA; Macias, JA; Manrique, I; Martín, M; Oruezabal, M, 2000) |
| "A significant response rate with oral tegafur and folinic acid in patients with heavily pretreated breast cancer was found." | 9.08 | Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. ( Albanell, J; Bellmunt, J; Carulla, J; Gallego, OS; Ribas, A; Solé, LA, 1995) |
| "A randomized study was performed in 35 centers in the Kinki area of Japan to determine the effectiveness of ftrorafur (FT) plus tamoxifen (TAM) compared with FT monotherapy in postoperative adjuvant therapy for breast cancer." | 9.08 | A randomized trial comparing ftorafur alone with ftorafur plus tamoxifen in postoperative adjuvant therapy for breast cancer. Kinki Area Research Group for Postoperative Adjuvant Therapy for Breast Cancer. ( Kosaki, G; Koyama, H; Nakao, K; Oshima, A; Sakai, K; Seno, T; Taguchi, T; Terasawa, T, 1996) |
| "A comparative, randomized trial was conducted to determine the efficacy of oral UFT (Tegafur and Uracil) versus 5-fluorouracil (5-FU) in combination with cyclophosphamide and doxorubicin in patients with metastatic breast cancer." | 9.08 | A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital. ( De Guzman, LM; Fernando, GY; Guancia, AA; Romana, IB; Samson, MC; Villalon, AH, 1997) |
| "The value of cyclophosphamide/methotrexate/5-fluorouracil (CMF)-type regimens in surgical adjuvant therapy in certain subsets of patients with axillary lymph node-negative breast cancer has been evaluated in Europe and the USA." | 9.08 | Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral uracil/tegafur versus 6-cycle cyclophosphamide/methotrexate/5-fluorouracil in high-risk node-negative breast cancer patients. ( Watanabe, T, 1998) |
| "Combination therapy consisting of cyclophosphamide (CPA), adriamycin (ADR), UFT and endocrine therapy of oophorectomy or tamoxifen (TAM) was given female patients with advanced or recurrent breast cancer." | 9.07 | [Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer]. ( Abe, R; Kiman, K; Kimijima, I; Nihei, M; Sakonji, M; Satomi, T; Suzuki, S; Tanaka, T, 1994) |
| "A double blind study to compare the efficacy of oral UFT (400 mg Tegafur (FT) plus 896 mg uracil/day) with that of oral FT (800 mg/day) on advanced breast cancer was performed between November, 1986, and November, 1989." | 9.07 | A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. ( Nomura, Y; Ohsaki, A; Tashiro, H, 1994) |
| "A prospective randomised multicentre clinical study was undertaken for 2 years and 3 months from November 1982, with the aim of examining the significance of using a combination of ftorafur (FT) and tamoxifen (TAM) for post-operative adjuvant therapy of breast cancer." | 9.07 | Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group. ( Asaishi, K; Hata, Y; Hayasaka, H; Mito, M; Samejima, N; Tanabe, T; Uchino, J, 1994) |
| "A randomized study assessing the efficacy of three treatment of ftorafur (FT), ftorafur plus Tamoxifen (TAM), and Tamoxifen in patients diagnosed as having stage II (N1b) or stage III breast cancer was carried out at 90 institutions in the Chubu district of Japan." | 9.07 | [A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan]. ( Kobayashi, S; Miyazaki, I; Mizumoto, R; Nimura, Y; Noguchi, M; Saji, S; Takagi, H; Takeuchi, S; Tsuda, H; Yoshida, M, 1993) |
| "Between February 1985 and October 1989, 26 patients previously treated for metastatic breast cancer received oral tegafur, at a median daily dose of 1200 mg." | 9.07 | Oral tegafur in the treatment of metastatic breast cancer: a phase II study. ( Kajanti, MJ; Maiche, AG; Pyrhönen, SO, 1993) |
| "Two hundred patients with node positive stage II breast cancer were randomised to four groups after radical mastectomy and axillary evacuation: (1) Postoperative radiotherapy, (2) Adjuvant chemotherapy with eight courses of CAFt (cyclophosphamide 500 mg m-2 + doxorubicin 40 mg/m-2 + ftorafur 20 mg kg-1 orally day 1-14) every fourth week, (3) Postoperative radiotherapy and adjuvant chemotherapy and (4) postoperative radiation, adjuvant chemotherapy and tamoxifen 40 mg daily for 2 years." | 9.07 | The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial. ( Blomqvist, C; Elomaa, I; Gröhn, P; Heinonen, E; Hietanen, T; Rissanen, P; Tiusanen, K, 1992) |
| "Of 47 consecutive patients with advanced breast cancer, we randomly assigned 24 to receive Arm A; ACF alone (Adriamycin, Cyclophosphamide, Ftorafur) and 23 to receive Arm B; 2 cycles of ACF alternating one cycle of MVMF (Mitomycin C, Vincristine, Methotrexate, Ftorafur--a combination of drugs not cross-resistant with ACF)." | 9.06 | [A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer]. ( Horikoshi, N; Inagaki, J; Inoue, K; Ito, Y; Mukaiyama, T; Nakamura, T; Ogawa, M; Tada, A; Ueno, K; Yamazaki, H, 1989) |
| "A prospective randomized study was performed in 22 institutions from July 1978, to evaluate the efficiency of long-term adjuvant chemotherapy with tegafur alone for primary breast cancer." | 9.06 | [Cooperative study of postoperative long-term adjuvant therapy of breast cancer. First study of a series--comparative study between postoperative tegafur administration and no adjuvant chemotherapy]. ( Iwasa, Z; Kawahara, T; Kousaki, G; Okajima, K; Okamoto, E; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T; Utsunomiya, J, 1988) |
| "A randomized controlled trial envelope method was conducted in 126 cases of recurrent breast cancer to compare the antitumor efficacy and toxicity of spansule (SF-SP) and gastro-soluble tegafur." | 9.05 | [Comparative study on two different types of tegafur for recurrent breast cancer]. ( Taguchi, T, 1984) |
| "A prospective randomized trial was conducted comparing the clinical response of 60 patients with advanced breast cancer to a combination of adriamycin, cyclophosphamide, and oral ftorafur (ACF), or to a combination of ACF plus methotrexate (ACFM)." | 9.05 | A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Miyamoto, H; Nakada, H; Ogawa, M; Usui, N, 1984) |
| "A prospective randomized trial was conducted to compare the clinical responses of sixty patients with advanced breast cancer to a combination of adriamycin, cyclophosphamide and oral ftorafur (ACF), or to a combination of ACF plus methotrexate (ACFM)." | 9.05 | [A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Tada, A; Usui, N; Yamazaki, H, 1984) |
| "During the past 4 years, a sequential study was conducted to compare the effect of tamoxifen (TAM) alone and TAM plus 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) in the treatment of advanced breast cancer." | 9.05 | Tamoxifen alone versus tamoxifen plus 1-(2-tetrahydrofuryl)-5-fluorouracil in the treatment of advanced breast cancer: a sequential trial. ( Koyama, H; Terasawa, T; Wada, T, 1981) |
| "Oral fluoropyrimidine anticancer agents (oral 5-fluorouracil [5-FU]) able to be used as chemotherapy for breast cancer include tegafur-uracil (UFT), tegafur-gimeracil-oteracil potassium (S-1), doxifluridine, and capecitabine." | 8.89 | Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer. ( Watanabe, T, 2013) |
| "In Japan, the history of postoperative chemotherapy for breast cancer started with 5-fluorouracil (5-FU), launched in the 1980s." | 8.86 | Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan. ( Nakayama, T; Noguchi, S, 2010) |
| "Use of continuous-infusion 5-fluorouracil (5-FU) for the treatment of metastatic breast cancer has met with some success in recent years." | 8.80 | Epirubicin, cyclophosphamide, and UFT plus oral calcium folinate in advanced breast cancer. ( Smith, IE, 1999) |
| "Irinotecan is rarely used on the metastatic breast cancer (MBC) setting." | 7.96 | Pilot Study of Irinotecan and S-1 (IRIS) for Advanced and Metastatic Breast Cancer. ( Anan, K; Furusawa, H; Kai, Y; Kamada, Y; Mitsuyama, S; Miyara, K; Sagara, Y; Tamura, K; Tanaka, M; Tanaka, T; Uga, T, 2020) |
| "We report the case of a patient in which S-1 plus anastrozole was administered as first-line chemotherapy for Stage IV breast cancer with skin invasion, multiple lymph node metastasis, and lymphangitis carcinomatosis." | 7.85 | [A Case of Stage IV Breast Cancer with Extensive Metastasis Successfully Treated with S-1 plus Anastrozole Therapy]. ( Akami, T; Hatakeyama, T; Matsumura, A; Mugitani, T; Ogino, S; Okano, S; Sakai, T, 2017) |
| "We report a case of Stage IV breast cancer in a 62-year-old woman who responded well to alternate-day S-1/letrozole combination therapy." | 7.81 | [Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis--A Case Report]. ( Fujita, Y; Muranishi, Y; Nakayama, I, 2015) |
| "Tegafur-gimeracil-oteracil potassium (TS-1)is a drug that is used mainly as a third-line treatment or beyond for metastatic breast cancer(MBC)." | 7.80 | Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer: a single-center retrospective study. ( Ishizuna, K; Kawashima, M; Kojima, M; Ninomiya, J; Nozaki, M; Ogawa, T; Tsuji, E; Ueda, Y; Yamagishi, H, 2014) |
| "For a case of recurrent breast cancer with multiple bone metastasis, an oral pyrimidine fluoride-based anti-cancer drug S -1, and zoledronic acid(a third-generation bisphosphonate formulation), were prescribed in experiments to test their efficacy." | 7.79 | [A case of recurrent breast cancer with multiple bone metastasis successfully treated with S-1 and zoledronic acid therapy]. ( Kaneko, M; Murata, T; Yamada, T; Yoshino, H, 2013) |
| "We report a long-term complete response (CR) in a patient with postoperative recurrent breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid." | 7.76 | [Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid]. ( Fujiwara, I; Ichida, M; Matsumoto, M; Mizuta, M; Mizuta, N; Nishiyama, A; Ohashi, M; Sakaguchi, K; Umeda, Y, 2010) |
| " To determine whether nucleoside metabolizing enzymes could be used to predict the response to UFT treatment in women with primary breast cancer, we retrospectively analyzed archived tumor tissue samples obtained from the 3rd Adjuvant Chemo-Endocrine Therapy for Breast Cancer (ACETBC) study, in which adjuvant treatment with tamoxifen (TAM) plus UFT for 2 years was compared with TAM alone for 2 years." | 7.74 | Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. ( Abe, O; Akiyama, F; Ikeda, T; Kurosumi, M; Sakamoto, G; Toi, M; Tsuda, H, 2007) |
| " Based on this enzymatic characteristic of pulmonary metastases of breast cancer in regard to 5-FU metabolism, we investigated the antitumor activity of two types of oral 5-FU prodrugs, with and without paclitaxel, on both orthotopically implanted breast tumors and metastatic lung tumors in mice." | 7.72 | Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. ( Fujioka, A; Fukushima, M; Kitazato, K; Nagayama, S; Nakagawa, F; Nukatsuka, M; Oshimo, H; Sugimoto, Y; Uchida, J, 2004) |
| "In this study, we evaluated the safety and efficacy of a combination of oral ftorafur administered together with intramuscular thiotepa as adjuvant chemotherapy for "early" breast cancer patients." | 7.71 | Oral ftorafur plus intramuscular thiotepa as adjuvant chemotherapy in patients with breast cancer. ( Galmarini, CM; Galmarini, D; Galmarini, FC; Garbovesky, C, 2002) |
| "We evaluated combination therapy for advanced and recurrent breast cancer with cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), UFT (uracil and tegafur), and tamoxifen (Nolvadex) (CAUT), designed as chemoendocrine therapy with a high antitumor effect and less severe adverse reactions." | 7.70 | Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen. ( Adachi, Y; Fukuda, M; Fukuma, E; Nakayama, Y; Nishikawa, T; Ogata, H; Ohta, T; Shimizu, K; Yamaguchi, S, 1999) |
| "Two female breast cancer patients who received combined tamoxifen and tegafur as postsurgical adjuvant therapy developed severe hepatotoxicity after being treated for three and eight months, respectively." | 7.69 | Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy. ( Abe, J; Hirayama, C; Maruyama, S; Matsui, K; Tanaka, J, 1995) |
| "The elevation of serum iron level was noted in six out of 45 patients with breast cancers who were treated by medroxyprogesterone acetate (MPA) in Kinki University Hospital." | 7.68 | [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer]. ( Houjou, T; Kadota, K; Mori, N; Wada, T; Watatani, M; Yasutomi, M, 1991) |
| "A 44-year-old premenopausal woman with metastatic breast cancer to the bones was treated with tamoxifen and tegafur followed by a minimal dose of tamoxifen alone, with complete response for more than 90 months." | 7.67 | [A case of recurrent breast cancer responding to long-term administration of tamoxifen]. ( Inaji, H; Kobayashi, T; Maeura, Y; Mori, T; Yayoi, E, 1984) |
| "A 51-year-old female with advanced breast cancer involving multiple bone metastases was daily administered 400 mg of UFT and 20 mg of tamoxifen." | 7.67 | [A case of breast cancer with multiple bone metastases effectively treated with UFT and tamoxifen]. ( Endo, F; Ishii, T; Kito, T, 1989) |
| "Since June 1984, 23 cases of progressive or recurrent breast cancers were treated with combination chemotherapy of VAM-UFT consisting of vincristine, adriamycin, mitomycin C and UFT." | 7.67 | [Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer]. ( Hozumi, T; Imamura, Y; Irie, K; Katou, J; Matsushita, K; Okutani, T; Oya, M; Yasutake, K; Yoshimura, Y, 1989) |
| "Medroxyprogesterone acetate (MPA) plus Tegafur (TGF) therapy was performed to evaluate the efficacy in a treatment for Tamoxifen- and Adriamycin-resistant advanced breast cancers." | 7.67 | [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers]. ( Aizawa, M; Houjou, T; Kadota, K; Kurooka, K; Matunami, N; Mori, N; Morikawa, E; Nakano, K; Wada, T; Yamato, M, 1989) |
| "A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 7.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
| "The therapeutic efficacy of a regimen containing epirubicin (EPI) and vindesine (VDS) was evaluated in patients with breast cancer who were given a dose of 20 mg EPI and 3 mg VDS every 2 weeks." | 7.67 | [Combination chemotherapy using low-dose epirubicin and vindesine in patients with metastatic breast cancer]. ( Kawahara, T; Nakayama, H; Takatsuka, Y, 1988) |
| "A 36-year-old woman was treated with tamoxifen for lung metastasis of breast cancer and had marked hyperlipoproteinemia with giant fatty liver, high plasma triglyceride levels (3673 mg/dl), and increased levels of very low density lipoprotein (VLDL) and intermediate density lipoprotein (UDL)." | 7.67 | [A case report of hyperlipemia with giant fatty liver during adjuvant endocrine therapy by tamoxifen]. ( Kitabayashi, K; Koshino, Y; Mabuchi, H; Miyazaki, I; Nakano, Y; Noguchi, M; Nonomura, A; Tajiri, K; Taniya, T, 1987) |
| "Multiconcomitant therapy using adriamycin, cyclophosphamide, tegafur and tamoxifen was employed as chemo-endocrine therapy against progressive breast cancer, and the effects, toxicity and prognosis associated with this regimen were studied." | 7.67 | [ACFT therapy using adriamycin, cyclophosphamide, tegafur and tamoxifen against progressive breast cancer]. ( Meguro, F; Tamura, M; Watanabe, Y, 1988) |
| "Twenty-nine patients with metastatic breast cancer were treated with a combination chemotherapy consisting of Epirubicin 50 mg/m2 IV on day 1, Cyclophosphamide 500 mg/m2 IV on day 1 and Ftorafur 800 mg/day PO every day (ECF therapy)." | 7.67 | [Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer]. ( Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Mizunuma, N; Mukaiyama, T; Ogawa, M; Shinagawa, K; Tabata, M, 1988) |
| "Ninety-one patients with metastatic breast cancer who had been previously treated with anthracyclines and/or taxanes were treated with UFT and leucovorin, given orally, for the first 28 days of a 35-day cycle." | 6.75 | A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. ( Booser, DJ; Heim, W; Hortobagyi, GN; Hutchins, L; Kirshner, J; Mason, B; Rivera, E, 2010) |
| "Ninety-four patients with metastatic breast cancer who had been previously treated with anthracyclines and/or taxanes were treated with UFT and leucovorin, given orally, for the first 28 days of a 35-day cycle." | 6.75 | A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. ( Gore, I; Hermann, R; Hortobagyi, GN; Ibrahim, NK; Karwal, M; Murray, JL; Watkins, SP; Young, RR, 2010) |
| " Our results confirmed that longterm postoperative therapy with UFT alone was feasible, provided that early adverse events are carefully monitored." | 6.74 | [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer]. ( Noguchi, S; Taguchi, T, 2009) |
| "The pharmacokinetics of ftorafur, 5-fluorouracil (5FU) and uracil were investigated in order to built a population pharmacokinetic model for the anticancer drug UFT, administered with leucovorin and vinorelbine." | 6.71 | Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. ( Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003) |
| "The treatment efficacy of advanced breast cancer is still not promising." | 5.42 | Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study. ( Chen, Y; Han, C; Jiao, S; Li, J; Linghu, R; Si, W; Yang, B; Yang, J; You, J; Zhang, X; Zhu, Y, 2015) |
| "We diagnosed her case to be bilateral breast cancer with peritonitis carcinomatosa, lymph node metastases and bony metastases." | 5.35 | [A case of bilateral breast cancer and metastatic gastric cancer with peritonitis carcinomatosa successfully treated with a combination therapy of S-1 and paclitaxel]. ( Aramaki, N; Iizuka, M; Kuranami, M; Kurita, A; Miyauchi, K; Nakakuma, T; Sengoku, N; Shiozawa, K; Ueno, S, 2009) |
| "To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice." | 5.31 | [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]. ( Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002) |
| "We recently established a metastasis model in nude mice using the MKL-4 cell line, a contransfectant of the MCF-7 human breast cancer cell line with fgf-4 and lacZ in which micrometastases in several organs can be quantitatively observed." | 5.30 | Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. ( Dickson, RB; Fujioka, A; Fukumori, H; Kurebayashi, J; Kurosumi, M; Nukatsuka, M; Saito, H; Sonoo, H; Takeda, S; Unemi, N, 1997) |
| "Patients with HER2-negative and endocrine treatment-resistant breast cancer with metastasis or recurrence after surgery were randomly assigned to receive first-line taxane or S-1." | 5.27 | Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer. ( Fukuda, T; Hagiwara, Y; Kawahara, T; Mukai, H; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Taira, N; Uemura, Y; Watanabe, T, 2018) |
| "This phase II study evaluated the efficacy and safety of anastrozole concurrent with tegafur/uracil (UFT) as neoadjuvant therapy for ER-positive postmenopausal breast cancer." | 5.27 | Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). ( Aono, T; Ito, T; Kagimura, T; Masuda, N; Matsunami, N; Miyoshi, Y; Nakayama, T; Noguchi, S; Sagara, Y; Taguchi, T; Takashima, T, 2018) |
| "We investigated the efficacy and safety of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium (TS-1) in patients with metastatic and recurrent breast cancer (MRBC), and the association between irinotecan metabolizing enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms and adverse events." | 5.20 | Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. ( Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U, 2015) |
| "We conducted a phase I study of a weekly nab-paclitaxel and S-1 combination therapy in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer." | 5.20 | Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer. ( Aruga, T; Iwasa, T; Komoike, Y; Kuroi, K; Makimura, C; Miyazaki, M; Nakagawa, K; Nishina, S; Okamoto, K; Saeki, T; Shigekawa, T; Tanizaki, J; Tsurutani, J; Yamashita, T, 2015) |
| "Capecitabine and S-1 are orally administered fluorinated pyrimidines with high-level activity against metastatic breast cancer (MBC)." | 5.20 | Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial. ( Ariyoshi, K; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Nagumo, Y; Odagiri, H; Sueoka, N; Teramoto, S; Tsubota, Y; Yamaguchi, T; Yamamoto, C; Yamamoto, D, 2015) |
| "A prospective randomized clinical trial was conducted to evaluate the efficacy of tamoxifen plus doxorubicin and cyclophosphamide compared to tamoxifen plus tegafur-uracil as an adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC)." | 5.19 | Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404. ( Ando, J; Aogi, K; Fukuda, H; Fukutomi, T; Inoue, K; Iwata, H; Kinoshita, T; Nakamura, K; Shibata, T; Shien, T; Takashima, S, 2014) |
| "This Phase II trial investigated the combination paclitaxel (P) and uracil-tegafur (UFT) in patients with metastatic breast cancer (MBC)." | 5.15 | Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial. ( Bazan, F; Chaigneau, L; Demarchi, M; Dufresne, A; N'guyen, T; Pivot, X; Stein, U; Thierry Vuillemin, A; Villanueva, C, 2011) |
| "To assess the efficacy and safety profile of biweekly vinorelbine and tegafur/uracil (UFT) as treatment in patients with metastatic breast cancer previously treated with anthracyclines and taxanes." | 5.15 | Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000-02 phase II study. ( Antón, A; Barnadas, A; Florián, J; Gayo, J; González-Quintás, A; Lao, J; Lomas, M; Margelí, M; Paules, AB; Ramos, M; Ribelles, N, 2011) |
| "The primary aim of this study was to compare the effectiveness of oral uracil-tegafur (UFT) with that of classical cyclophosphamide, methotrexate, and fluorouracil (CMF) given as postoperative adjuvant treatment to women with node-negative, high-risk breast cancer." | 5.14 | Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. ( Iwata, H; Kitaya, T; Kohno, N; Nakagami, K; Ohashi, Y; Sakamoto, G; Sano, M; Shimozuma, K; Sonoo, H; Takashima, S; Tokuda, Y; Tsuda, H; Watanabe, T; Yoshimoto, M, 2009) |
| " Therefore, we compared UFT with a combination therapy of cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients who had undergone curative surgery for axillary lymph node-positive breast cancer." | 5.14 | Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study. ( Asaga, T; Higaki, K; Inaji, H; Ito, T; Koh, J; Kohno, N; Komichi, H; Koyama, H; Kyono, S; Mitsuyama, S; Nishikawa, H; Ogita, M; Okamura, K; Osaki, A; Park, Y; Saito, T; Suzuki, T; Tanaka, F; Yamazaki, K, 2009) |
| "Two randomized clinical studies comparing the efficacy of oral UFT (2 years) with that of classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) (six courses) have been conducted in patients with resected early breast cancer." | 5.14 | Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial). ( Inaji, H; Koyama, H; Ohashi, Y; Sano, M; Suzuki, T; Watanabe, T, 2010) |
| "To evaluate the efficacies of cyclophosphamide, methotrexate, and fluorouracil (CMF) and tegafur-uracil (UFT) as adjuvant therapy in patients with resected stage I-IIIA breast cancer by immunohistochemistry (IHC)-based subtype and to determine the relationships between clinicopathological factors and long-term outcomes." | 5.12 | Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial). ( Akiyama, F; Inaji, H; Kurosumi, M; Masuda, N; Ohashi, Y; Ohno, S; Ohsumi, S; Saji, S; Sato, N; Shimomura, A; Takao, S; Tokuda, Y; Tsuda, H; Watanabe, T, 2021) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 5.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "The present study assesses the effects of neo-adjuvant chemotherapy (NAC) with uracil and tegafur (UFT) alone vs UFT plus cyclophosphamide (CPA), on the activity of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) in breast cancer tissues." | 5.12 | Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase. ( Fukushima, M; Hashimoto, K; Iguchi, C; Itakura, M; Kodama, H; Koike, M; Maruyama, R; Nio, Y; Toga, T, 2007) |
| "This article reports the results of a pooled analysis of six randomized trials conducted to study the efficacy of uracil and tegafur (UFT) in the adjuvant treatment of node-negative breast cancer patients." | 5.11 | Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. ( Abe, O; Abe, R; Akazawa, K; Koyama, H; Miura, S; Noguchi, S; Sugimachi, K; Uchino, J, 2005) |
| "A prospective randomized multi-center study was undertaken for 2 years and 3 months from November 1982, with the aim of examining the significance of using a combination of futraful (FT) and tamoxifen (TAM) for postoperative adjuvant therapy for stage II breast cancer after curative surgery." | 5.10 | Ten-year results of a randomized trial on adjuvant chemo-endocrine therapy with tamoxifen for stage II breast cancer. ( Asaishi, K; Hata, Y; Hirata, K; Kato, H; Okazaki, M; Okushiba, S; Takahashi, H; Todo, S; Uchino, J, 2003) |
| "To determine the maximum tolerated doses, toxicities, and therapeutic effect of an oral chemotherapy regimen consisting of uracil-ftorafur, etoposide, and leucovorin for metastatic breast cancer." | 5.10 | Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. ( Carlson, RW; Grekowicz, A; Hartman, AR; Lum, BL; Schurman, C; Shapiro, R; Sikic, BI; Stockdale, FE, 2003) |
| "This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer." | 5.09 | Paclitaxel, UFT, and calcium folinate in metastatic breast cancer. ( Blanke, C; Cohen, A; Dickson, NR; Hande, K; Johnson, D; Nicholson, BP, 1999) |
| "This phase I study was designed to determine the maximum tolerated dose (MTD) and dose-limiting side effects of combination treatment with paclitaxel (Taxol) and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral calcium folinate (Orzel) for advanced metastatic breast cancer." | 5.09 | Paclitaxel and UFT plus oral calcium folinate in pretreated metastatic breast cancer. ( Benner, S; Borquez, D; Harstrick, A; Klaassen, U; Lang, S; Oberhoff, C; Seeber, S, 1999) |
| "Paclitaxel (Taxol) is one of the most active drugs in the treatment of ovarian and breast cancers." | 5.09 | UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer. ( Dethling, J; Kühnle, H; Lück, HJ; Scholz, U, 1999) |
| "A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive primary breast cancer." | 5.09 | UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group. ( Asaishi, K; Hata, Y; Hirata, K; Kubo, Y; Mito, M; Ogita, M; Tanabe, T; Uchino, J, 1999) |
| "This phase I study was undertaken to define the maximum tolerated dose, dose-limiting toxicity, and recommended dosage of UFT (uracil and tegafur) plus oral calcium folinate (Orzel) and vinorelbine (Navelbine) in combination treatment of metastatic breast cancer in patients who have received one prior chemotherapy regimen." | 5.09 | UFT plus oral calcium folinate/vinorelbine for advanced breast cancer. ( Déporte-Fety, R; Fumoleau, P; Kerbrat, P; Laguerre, B, 1999) |
| "Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation." | 5.09 | Uracil/tegafur plus oral calcium folinate in advanced breast cancer. ( Alvarez, AM; Bonamasa, M; Bruno, M; Coppola, F; Cuevas, MA; Elli, A; Fein, L; Jovtis, S; Lerzo, G; Mickiewicz, E; Pedraza, C; Richardet, E; Suarez, LA; Uranga, G; Ventriglia, M, 1999) |
| "Thirty patients with pretreated advanced breast cancer were enrolled in a study aimed to establish the maximum tolerated dose and to evaluate the efficacy of oral idarubicin (12 mg/m2/day for 3 days every 4 weeks) with tegafur and levo-folinate (200 mg/m2/day and 50 mg/day, respectively, for a minimum of 6 days, increasing the dose and duration according to a modified Fibonacci scheme)." | 5.09 | Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancer. ( Cilenti, G; Lelli, G; Suriano, A; Tartarone, A; Tozzi, L, 1999) |
| " Moreover, combination therapy with paclitaxel and fluorouracil (5-FU) exhibits high activity in anthracycline-pretreated breast cancer patients: recent studies report response rates of 54% to 69%." | 5.09 | A phase I study. UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer. ( Canzler, U; Kühnle, H; Lück, HJ; Robner, D; Scholz, U, 2000) |
| "This article describes the design and early results of an open-label, nonrandomized phase I/II trial of oral UFT plus leucovorin therapy in combination with bolus injections of epirubicin and cyclophosphamide in patients with advanced or metastatic breast cancer." | 5.09 | UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer. ( Gregory, RK; Johnston, SR; Miles, D; Smith, IE, 2000) |
| "Thirty-four patients with metastatic breast cancer (MBC) who had progression of disease after high-dose chemotherapy (HDCT) with peripheral blood progenitor cell support (PBPC) had methotrexate, uracil and tegafur (UFT), and leucovorin (MUL) therapy administered: methotrexate administered intramuscularly in combination with UFT given orally and leucovorin given orally." | 5.09 | Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: a phase II study. ( Casado, A; Diaz-Rubio, E; Garcia-Carbonero, I; Garcia-Saenz, JA; Macias, JA; Manrique, I; Martín, M; Oruezabal, M, 2000) |
| "A significant response rate with oral tegafur and folinic acid in patients with heavily pretreated breast cancer was found." | 5.08 | Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. ( Albanell, J; Bellmunt, J; Carulla, J; Gallego, OS; Ribas, A; Solé, LA, 1995) |
| "A randomized study was performed in 35 centers in the Kinki area of Japan to determine the effectiveness of ftrorafur (FT) plus tamoxifen (TAM) compared with FT monotherapy in postoperative adjuvant therapy for breast cancer." | 5.08 | A randomized trial comparing ftorafur alone with ftorafur plus tamoxifen in postoperative adjuvant therapy for breast cancer. Kinki Area Research Group for Postoperative Adjuvant Therapy for Breast Cancer. ( Kosaki, G; Koyama, H; Nakao, K; Oshima, A; Sakai, K; Seno, T; Taguchi, T; Terasawa, T, 1996) |
| "Between 1985 and 1988, the effect of using ftorafur (FT) or PSK (an immunotherapy agent) in combination with the conventional postoperative adjuvant therapy using mitomycin (MMC) plus tamoxifen (TAM) was assessed in stage II, oestrogen receptor-positive (ER+) breast cancer patients." | 5.08 | Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Can ( Dohi, K; Monden, Y; Morimoto, T; Nomura, Y; Ogawa, M; Ogawa, N; Orita, K; Sugimachi, K; Toge, T, 1996) |
| "A comparative, randomized trial was conducted to determine the efficacy of oral UFT (Tegafur and Uracil) versus 5-fluorouracil (5-FU) in combination with cyclophosphamide and doxorubicin in patients with metastatic breast cancer." | 5.08 | A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital. ( De Guzman, LM; Fernando, GY; Guancia, AA; Romana, IB; Samson, MC; Villalon, AH, 1997) |
| "Between 1989 and 1993, 409 evaluable patients with breast cancer have been treated with tegafur and uracil (UFT) in an adjuvant setting in two different trials." | 5.08 | UFT in combination as adjuvant therapy for breast cancer. Grupo Oncologico de Sevilla Seville, Spain. ( Codes, M; Dugue, A; Garcia, E; Iglesias, L; Moreno, JA; Murillo, E; Torrija, E; Virizuela, JA, 1997) |
| "The value of cyclophosphamide/methotrexate/5-fluorouracil (CMF)-type regimens in surgical adjuvant therapy in certain subsets of patients with axillary lymph node-negative breast cancer has been evaluated in Europe and the USA." | 5.08 | Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral uracil/tegafur versus 6-cycle cyclophosphamide/methotrexate/5-fluorouracil in high-risk node-negative breast cancer patients. ( Watanabe, T, 1998) |
| "Combination therapy consisting of cyclophosphamide (CPA), adriamycin (ADR), UFT and endocrine therapy of oophorectomy or tamoxifen (TAM) was given female patients with advanced or recurrent breast cancer." | 5.07 | [Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer]. ( Abe, R; Kiman, K; Kimijima, I; Nihei, M; Sakonji, M; Satomi, T; Suzuki, S; Tanaka, T, 1994) |
| "A double blind study to compare the efficacy of oral UFT (400 mg Tegafur (FT) plus 896 mg uracil/day) with that of oral FT (800 mg/day) on advanced breast cancer was performed between November, 1986, and November, 1989." | 5.07 | A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. ( Nomura, Y; Ohsaki, A; Tashiro, H, 1994) |
| "A prospective randomised multicentre clinical study was undertaken for 2 years and 3 months from November 1982, with the aim of examining the significance of using a combination of ftorafur (FT) and tamoxifen (TAM) for post-operative adjuvant therapy of breast cancer." | 5.07 | Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group. ( Asaishi, K; Hata, Y; Hayasaka, H; Mito, M; Samejima, N; Tanabe, T; Uchino, J, 1994) |
| "A randomized study assessing the efficacy of three treatment of ftorafur (FT), ftorafur plus Tamoxifen (TAM), and Tamoxifen in patients diagnosed as having stage II (N1b) or stage III breast cancer was carried out at 90 institutions in the Chubu district of Japan." | 5.07 | [A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan]. ( Kobayashi, S; Miyazaki, I; Mizumoto, R; Nimura, Y; Noguchi, M; Saji, S; Takagi, H; Takeuchi, S; Tsuda, H; Yoshida, M, 1993) |
| "Between February 1985 and October 1989, 26 patients previously treated for metastatic breast cancer received oral tegafur, at a median daily dose of 1200 mg." | 5.07 | Oral tegafur in the treatment of metastatic breast cancer: a phase II study. ( Kajanti, MJ; Maiche, AG; Pyrhönen, SO, 1993) |
| "Two hundred patients with node positive stage II breast cancer were randomised to four groups after radical mastectomy and axillary evacuation: (1) Postoperative radiotherapy, (2) Adjuvant chemotherapy with eight courses of CAFt (cyclophosphamide 500 mg m-2 + doxorubicin 40 mg/m-2 + ftorafur 20 mg kg-1 orally day 1-14) every fourth week, (3) Postoperative radiotherapy and adjuvant chemotherapy and (4) postoperative radiation, adjuvant chemotherapy and tamoxifen 40 mg daily for 2 years." | 5.07 | The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial. ( Blomqvist, C; Elomaa, I; Gröhn, P; Heinonen, E; Hietanen, T; Rissanen, P; Tiusanen, K, 1992) |
| "Of 47 consecutive patients with advanced breast cancer, we randomly assigned 24 to receive Arm A; ACF alone (Adriamycin, Cyclophosphamide, Ftorafur) and 23 to receive Arm B; 2 cycles of ACF alternating one cycle of MVMF (Mitomycin C, Vincristine, Methotrexate, Ftorafur--a combination of drugs not cross-resistant with ACF)." | 5.06 | [A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer]. ( Horikoshi, N; Inagaki, J; Inoue, K; Ito, Y; Mukaiyama, T; Nakamura, T; Ogawa, M; Tada, A; Ueno, K; Yamazaki, H, 1989) |
| "A prospective randomized study was performed in 22 institutions from July 1978, to evaluate the efficiency of long-term adjuvant chemotherapy with tegafur alone for primary breast cancer." | 5.06 | [Cooperative study of postoperative long-term adjuvant therapy of breast cancer. First study of a series--comparative study between postoperative tegafur administration and no adjuvant chemotherapy]. ( Iwasa, Z; Kawahara, T; Kousaki, G; Okajima, K; Okamoto, E; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T; Utsunomiya, J, 1988) |
| "A randomized controlled trial envelope method was conducted in 126 cases of recurrent breast cancer to compare the antitumor efficacy and toxicity of spansule (SF-SP) and gastro-soluble tegafur." | 5.05 | [Comparative study on two different types of tegafur for recurrent breast cancer]. ( Taguchi, T, 1984) |
| "A prospective randomized trial was conducted comparing the clinical response of 60 patients with advanced breast cancer to a combination of adriamycin, cyclophosphamide, and oral ftorafur (ACF), or to a combination of ACF plus methotrexate (ACFM)." | 5.05 | A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Miyamoto, H; Nakada, H; Ogawa, M; Usui, N, 1984) |
| "A prospective randomized trial was conducted to compare the clinical responses of sixty patients with advanced breast cancer to a combination of adriamycin, cyclophosphamide and oral ftorafur (ACF), or to a combination of ACF plus methotrexate (ACFM)." | 5.05 | [A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Tada, A; Usui, N; Yamazaki, H, 1984) |
| "During the past 4 years, a sequential study was conducted to compare the effect of tamoxifen (TAM) alone and TAM plus 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) in the treatment of advanced breast cancer." | 5.05 | Tamoxifen alone versus tamoxifen plus 1-(2-tetrahydrofuryl)-5-fluorouracil in the treatment of advanced breast cancer: a sequential trial. ( Koyama, H; Terasawa, T; Wada, T, 1981) |
| "Oral fluoropyrimidine anticancer agents (oral 5-fluorouracil [5-FU]) able to be used as chemotherapy for breast cancer include tegafur-uracil (UFT), tegafur-gimeracil-oteracil potassium (S-1), doxifluridine, and capecitabine." | 4.89 | Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer. ( Watanabe, T, 2013) |
| "In Japan, the history of postoperative chemotherapy for breast cancer started with 5-fluorouracil (5-FU), launched in the 1980s." | 4.86 | Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan. ( Nakayama, T; Noguchi, S, 2010) |
| "For several decades fluoropyrimidines, especially 5-fluorouracil (5-FU), have played a role in standard chemotherapy regimens for a range of solid tumours, including breast and colorectal cancers." | 4.81 | New options for outpatient chemotherapy--the role of oral fluoropyrimidines. ( Coleman, R; Cunningham, D, 2001) |
| "Three oral 5-fluorouracil (5-FU) therapies have been approved by the US Food and Drug Administration or are in development for the treatment of patients with breast cancer: capecitabine, UFT, and 5-FU/eniluracil." | 4.80 | Oral 5-FU analogues in the treatment of breast cancer. ( Bunnell, CA; Winer, EP, 1998) |
| "After nearly four decades of clinical experience with the fluoropyrimidines, 5-fluorouracil (5-FU) remains an integral part of chemotherapy for colorectal cancer." | 4.80 | Fluoropyrimidines: a critical evaluation. ( Brito, RA; Hoff, PM; Medgyesy, D; Pazdur, R; Ravandi-Kashani, F; Royce, ME; Zukowski, TH, 1999) |
| "Use of continuous-infusion 5-fluorouracil (5-FU) for the treatment of metastatic breast cancer has met with some success in recent years." | 4.80 | Epirubicin, cyclophosphamide, and UFT plus oral calcium folinate in advanced breast cancer. ( Smith, IE, 1999) |
| "Irinotecan is rarely used on the metastatic breast cancer (MBC) setting." | 3.96 | Pilot Study of Irinotecan and S-1 (IRIS) for Advanced and Metastatic Breast Cancer. ( Anan, K; Furusawa, H; Kai, Y; Kamada, Y; Mitsuyama, S; Miyara, K; Sagara, Y; Tamura, K; Tanaka, M; Tanaka, T; Uga, T, 2020) |
| "Metronomic chemotherapy using the 5-FU prodrug uracil-tegafur (UFT) and cyclophosphamide (CTX) was previously shown to only modestly delay primary tumor growth, but nevertheless markedly suppressed the development of micro-metastasis in an orthotopic breast cancer xenograft model, using the metastatic variant of the MDA-MB-231 cell line, 231/LM2-4." | 3.91 | Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. ( Cruz-Muñoz, W; Hileeto, D; Kerbel, RS; Man, S; Muñoz, R; Viloria-Petit, A; Wood, GA; Xu, P, 2019) |
| " SELECT BC compared S-1 and taxane as first-line treatment for metastatic breast cancer." | 3.91 | Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study. ( Chishima, T; Doihara, H; Hozumi, Y; Ishikawa, T; Miyoshi, Y; Morimoto, T; Mukai, H; Narui, K; Nishimura, R; Ohashi, Y; Ohno, S; Suto, A; Tamura, M; Uemura, Y; Yoshino, H; Zaha, H, 2019) |
| "We report the case of a patient in which S-1 plus anastrozole was administered as first-line chemotherapy for Stage IV breast cancer with skin invasion, multiple lymph node metastasis, and lymphangitis carcinomatosis." | 3.85 | [A Case of Stage IV Breast Cancer with Extensive Metastasis Successfully Treated with S-1 plus Anastrozole Therapy]. ( Akami, T; Hatakeyama, T; Matsumura, A; Mugitani, T; Ogino, S; Okano, S; Sakai, T, 2017) |
| "We report a case of Stage IV breast cancer in a 62-year-old woman who responded well to alternate-day S-1/letrozole combination therapy." | 3.81 | [Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis--A Case Report]. ( Fujita, Y; Muranishi, Y; Nakayama, I, 2015) |
| "Tegafur-gimeracil-oteracil potassium (TS-1)is a drug that is used mainly as a third-line treatment or beyond for metastatic breast cancer(MBC)." | 3.80 | Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer: a single-center retrospective study. ( Ishizuna, K; Kawashima, M; Kojima, M; Ninomiya, J; Nozaki, M; Ogawa, T; Tsuji, E; Ueda, Y; Yamagishi, H, 2014) |
| "For a case of recurrent breast cancer with multiple bone metastasis, an oral pyrimidine fluoride-based anti-cancer drug S -1, and zoledronic acid(a third-generation bisphosphonate formulation), were prescribed in experiments to test their efficacy." | 3.79 | [A case of recurrent breast cancer with multiple bone metastasis successfully treated with S-1 and zoledronic acid therapy]. ( Kaneko, M; Murata, T; Yamada, T; Yoshino, H, 2013) |
| "The present preclinical study was designed to evaluate a new combination therapy comprised of the aromatase inhibitor anastrozole (ANA) and the oral fluoropyrimidines, UFT and S-1 against the estrogen receptor (ER)-positive human breast cancer cell line MCF-7/Arom 14, which was stably transfected with the cDNA of human aromatase." | 3.77 | Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts. ( Abe, M; Kiniwa, M; Matsuo, K; Nakagawa, F; Noguchi, S; Nukatsuka, M; Saito, H; Shibata, J; Uchida, J, 2011) |
| "We report a long-term complete response (CR) in a patient with postoperative recurrent breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid." | 3.76 | [Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid]. ( Fujiwara, I; Ichida, M; Matsumoto, M; Mizuta, M; Mizuta, N; Nishiyama, A; Ohashi, M; Sakaguchi, K; Umeda, Y, 2010) |
| "We retrospectively evaluated the activity and toxicity of uracil/tegafur (UFT) plus oral folinic acid in combination with vinorelbine (alternating intravenous (IV) on day 1 and oral on day 8) in patients with metastatic breast cancer." | 3.75 | UFT plus oral folinic acid with alternating oral and intravenous vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. ( Alici, S; Alkis, N; Benekli, M; Buyukberber, S; Celenkoglu, G; Coşkun, U; Kaya, AO; Ozkan, M; Sevinc, A; Uncu, D, 2009) |
| "High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer." | 3.74 | [Evaluation of combination therapy of high-dose toremifene and oral chemotherapy]. ( Murakami, S; Yamamoto, Y, 2007) |
| " To determine whether nucleoside metabolizing enzymes could be used to predict the response to UFT treatment in women with primary breast cancer, we retrospectively analyzed archived tumor tissue samples obtained from the 3rd Adjuvant Chemo-Endocrine Therapy for Breast Cancer (ACETBC) study, in which adjuvant treatment with tamoxifen (TAM) plus UFT for 2 years was compared with TAM alone for 2 years." | 3.74 | Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. ( Abe, O; Akiyama, F; Ikeda, T; Kurosumi, M; Sakamoto, G; Toi, M; Tsuda, H, 2007) |
| "We had 2 patients with marked shrinkage of liver metastasis by administration of the oral fluorinated pyrimidine anticancer drug S-1 for advanced/recurrent breast cancer that was resistant to taxane and another antitumor drugs." | 3.73 | [Two patients effectively treated with S-1 therapy for liver metastasis of breast cancer resistant to other anticancer drugs]. ( Sato, Y, 2006) |
| " We tested a "doublet" combination metronomic chemotherapy treatment using two oral drugs, UFT, a 5-fluorouracil (5-FU) prodrug administered by gavage, and cyclophosphamide, for efficacy and toxicity in a new mouse model of advanced, terminal, metastatic human breast cancer." | 3.73 | Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. ( Francia, G; Kerbel, RS; Lee, CR; Man, S; Munoz, R; Shaked, Y; Wong, J, 2006) |
| " Based on this enzymatic characteristic of pulmonary metastases of breast cancer in regard to 5-FU metabolism, we investigated the antitumor activity of two types of oral 5-FU prodrugs, with and without paclitaxel, on both orthotopically implanted breast tumors and metastatic lung tumors in mice." | 3.72 | Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. ( Fujioka, A; Fukushima, M; Kitazato, K; Nagayama, S; Nakagawa, F; Nukatsuka, M; Oshimo, H; Sugimoto, Y; Uchida, J, 2004) |
| "In this study, we evaluated the safety and efficacy of a combination of oral ftorafur administered together with intramuscular thiotepa as adjuvant chemotherapy for "early" breast cancer patients." | 3.71 | Oral ftorafur plus intramuscular thiotepa as adjuvant chemotherapy in patients with breast cancer. ( Galmarini, CM; Galmarini, D; Galmarini, FC; Garbovesky, C, 2002) |
| " The degree of synergism between docetaxel and two oral fluoropyrimidines, tegafur and 5'-deoxy-5-fluorouridine (5'-dFUrd), was investigated in the KPL-4 human breast cancer xenograft model." | 3.71 | Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts. ( Kunisue, H; Kurebayashi, J; Kurosumi, M; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, S, 2001) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "We evaluated combination therapy for advanced and recurrent breast cancer with cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), UFT (uracil and tegafur), and tamoxifen (Nolvadex) (CAUT), designed as chemoendocrine therapy with a high antitumor effect and less severe adverse reactions." | 3.70 | Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen. ( Adachi, Y; Fukuda, M; Fukuma, E; Nakayama, Y; Nishikawa, T; Ogata, H; Ohta, T; Shimizu, K; Yamaguchi, S, 1999) |
| "Two female breast cancer patients who received combined tamoxifen and tegafur as postsurgical adjuvant therapy developed severe hepatotoxicity after being treated for three and eight months, respectively." | 3.69 | Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy. ( Abe, J; Hirayama, C; Maruyama, S; Matsui, K; Tanaka, J, 1995) |
| "Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral UFT (tegafur and uracil) and oral leucovorin (the MUL regimen)." | 3.69 | Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support. ( Ayala, F; Casado, A; Diaz-Rubio, E; López-Martin, JA; Martin, M; Nieto, Y; Rodriguez-Lescure, A, 1997) |
| "A 74-year-old female with lung metastasis of breast cancer was treated with chemo-endocrine therapy (intravenous administration of epirubicin at 30 mg/2w, oral administration of UFT at 400 mg/day, alternate oral administration of medroxyprogesterone acetate at 800 mg/day and tamoxifen at 40 mg/day) and immuno-therapy (intravenous administration of lentinan at 2 mg/w)." | 3.68 | [A case of breast cancer with thrombosis during treatment of lung metastasis]. ( Kosaka, A; Sakaguchi, T; Watahiki, Y, 1993) |
| "The elevation of serum iron level was noted in six out of 45 patients with breast cancers who were treated by medroxyprogesterone acetate (MPA) in Kinki University Hospital." | 3.68 | [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer]. ( Houjou, T; Kadota, K; Mori, N; Wada, T; Watatani, M; Yasutomi, M, 1991) |
| "A 34-year-old female patient with breast cancer metastasizing to bone had a remission after a course of treatment with medroxyprogesterone acetate (MPA) 1,200 mg/day, but again had a metastasis to the lungs." | 3.68 | [A case of bone and lung metastasis of breast cancer successfully treated with radiotherapy, chemotherapy and endocrine therapy]. ( Harada, N; Kanda, K; Kida, H; Narita, K; Uchimura, M; Waki, S, 1990) |
| "A 44-year-old premenopausal woman with metastatic breast cancer to the bones was treated with tamoxifen and tegafur followed by a minimal dose of tamoxifen alone, with complete response for more than 90 months." | 3.67 | [A case of recurrent breast cancer responding to long-term administration of tamoxifen]. ( Inaji, H; Kobayashi, T; Maeura, Y; Mori, T; Yayoi, E, 1984) |
| "A 51-year-old female with advanced breast cancer involving multiple bone metastases was daily administered 400 mg of UFT and 20 mg of tamoxifen." | 3.67 | [A case of breast cancer with multiple bone metastases effectively treated with UFT and tamoxifen]. ( Endo, F; Ishii, T; Kito, T, 1989) |
| "Since June 1984, 23 cases of progressive or recurrent breast cancers were treated with combination chemotherapy of VAM-UFT consisting of vincristine, adriamycin, mitomycin C and UFT." | 3.67 | [Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer]. ( Hozumi, T; Imamura, Y; Irie, K; Katou, J; Matsushita, K; Okutani, T; Oya, M; Yasutake, K; Yoshimura, Y, 1989) |
| "Medroxyprogesterone acetate (MPA) plus Tegafur (TGF) therapy was performed to evaluate the efficacy in a treatment for Tamoxifen- and Adriamycin-resistant advanced breast cancers." | 3.67 | [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers]. ( Aizawa, M; Houjou, T; Kadota, K; Kurooka, K; Matunami, N; Mori, N; Morikawa, E; Nakano, K; Wada, T; Yamato, M, 1989) |
| "A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 3.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
| " Following our former report in which the combination effects of mitomycin C (MMC) and 5'-deoxy-5-fluorouridine (5'-DFUR) were clarified, combined applications of 4 drugs, vindesine (VDS), methotrexate (MTX), cisplatin (CDDP) and 5'-DFUR against 3 lines of human breast cancer (H-62, H-31, H-71), and one line each of gastric cancer (H-55) and colon cancer (H-110) xenografted into nude mice were evaluated in comparison with CAF (cyclophosphamide, adriamycin and 5-FU) therapy which is commonly used for breast cancer." | 3.67 | [Combination chemotherapy with 3 or 4 drugs on human breast and gastrointestinal cancer xenografts in nude mice (II)]. ( Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T, 1987) |
| "The therapeutic efficacy of a regimen containing epirubicin (EPI) and vindesine (VDS) was evaluated in patients with breast cancer who were given a dose of 20 mg EPI and 3 mg VDS every 2 weeks." | 3.67 | [Combination chemotherapy using low-dose epirubicin and vindesine in patients with metastatic breast cancer]. ( Kawahara, T; Nakayama, H; Takatsuka, Y, 1988) |
| " Fifty-seven patients with postoperative breast cancer received MMF (mitomycin, methotrexate, futraful therapy with SNMC and 60 were given MMF alone." | 3.67 | [Prevention of cancer chemotherapeutic agent-induced toxicity in postoperative breast cancer patients with glycyrrhizin (SNMC)]. ( Akimoto, M; Iwasaki, H; Kasai, M; Kimura, M; Matano, S; Nakajima, Y; Sawano, A, 1986) |
| "A 36-year-old woman was treated with tamoxifen for lung metastasis of breast cancer and had marked hyperlipoproteinemia with giant fatty liver, high plasma triglyceride levels (3673 mg/dl), and increased levels of very low density lipoprotein (VLDL) and intermediate density lipoprotein (UDL)." | 3.67 | [A case report of hyperlipemia with giant fatty liver during adjuvant endocrine therapy by tamoxifen]. ( Kitabayashi, K; Koshino, Y; Mabuchi, H; Miyazaki, I; Nakano, Y; Noguchi, M; Nonomura, A; Tajiri, K; Taniya, T, 1987) |
| "Multiconcomitant therapy using adriamycin, cyclophosphamide, tegafur and tamoxifen was employed as chemo-endocrine therapy against progressive breast cancer, and the effects, toxicity and prognosis associated with this regimen were studied." | 3.67 | [ACFT therapy using adriamycin, cyclophosphamide, tegafur and tamoxifen against progressive breast cancer]. ( Meguro, F; Tamura, M; Watanabe, Y, 1988) |
| "Menstrual status and ovarian function were studied in 24 premenopausal breast cancer patients receiving adjuvant therapy with chemotherapy and tamoxifen or chemotherapy alone." | 3.67 | [Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy]. ( Honjo, H; Oka, T; Okada, H; Yasumura, T, 1988) |
| "Twenty-nine patients with metastatic breast cancer were treated with a combination chemotherapy consisting of Epirubicin 50 mg/m2 IV on day 1, Cyclophosphamide 500 mg/m2 IV on day 1 and Ftorafur 800 mg/day PO every day (ECF therapy)." | 3.67 | [Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer]. ( Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Mizunuma, N; Mukaiyama, T; Ogawa, M; Shinagawa, K; Tabata, M, 1988) |
| "A total of 65 patients with advanced colorectal or breast cancer were given oral tegafur in the phase I study." | 3.66 | Phase I-II studies of oral tegafur (ftorafur). ( Ansfield, FJ; Kallas, GJ; Singson, JP, 1983) |
| "The aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy." | 2.87 | Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study. ( Fukuda, T; Hagiwara, Y; Kawahara, T; Mukai, H; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Taira, N; Uemura, Y; Watanabe, T, 2018) |
| "The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life." | 2.84 | Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. ( Akabane, H; Doihara, H; Fukuda, T; Hagiwara, Y; Kashiwaba, M; Mouri, M; Mukai, H; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Watanabe, T, 2017) |
| "This study evaluated the efficacy and safety of S-1 combined with docetaxel (SD) following doxorubicin plus cyclophosphamide (AC) as neoadjuvant therapy in patients with HER2-negative, stage II-III breast cancer." | 2.78 | S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. ( Chung, HC; Kim, EK; Kim, JH; Kim, MJ; Kim, SI; Koo, JS; Lee, S; Moon, YW; Park, BW; Park, S; Sohn, J, 2013) |
| "As there are no reports of S-1 in combination with trastuzumab in clinical settings, we evaluated the safety and efficacy of S-1 in combination with trastuzumab for human epidermal-growth factor receptor (HER2)-positive metastatic breast cancer (MBC) and determined the recommended dose (RD)." | 2.76 | Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. ( Ito, T; Kamigaki, S; Morita, S; Nakayama, T; Noguchi, S; Sakamoto, J; Taguchi, T; Takashima, T; Yoshidome, K, 2011) |
| "Ninety-one patients with metastatic breast cancer who had been previously treated with anthracyclines and/or taxanes were treated with UFT and leucovorin, given orally, for the first 28 days of a 35-day cycle." | 2.75 | A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. ( Booser, DJ; Heim, W; Hortobagyi, GN; Hutchins, L; Kirshner, J; Mason, B; Rivera, E, 2010) |
| "Ninety-four patients with metastatic breast cancer who had been previously treated with anthracyclines and/or taxanes were treated with UFT and leucovorin, given orally, for the first 28 days of a 35-day cycle." | 2.75 | A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. ( Gore, I; Hermann, R; Hortobagyi, GN; Ibrahim, NK; Karwal, M; Murray, JL; Watkins, SP; Young, RR, 2010) |
| "Patients with hormone-resistant breast cancer are assigned to either TS-1 (40-60 mg twice daily for 28 consecutive days, followed by a 14-day rest period) or standard chemotherapy (docetaxel 60-75 mg/m(2) at 3- or 4-week intervals, paclitaxel 175 mg/m(2) at 3- or 4-week intervals or paclitaxel 80-100 mg/m(2) weekly, followed by a 1-week rest period)." | 2.75 | Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC). ( Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T, 2010) |
| " Our results confirmed that longterm postoperative therapy with UFT alone was feasible, provided that early adverse events are carefully monitored." | 2.74 | [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer]. ( Noguchi, S; Taguchi, T, 2009) |
| "The pharmacokinetics of ftorafur, 5-fluorouracil (5FU) and uracil were investigated in order to built a population pharmacokinetic model for the anticancer drug UFT, administered with leucovorin and vinorelbine." | 2.71 | Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. ( Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003) |
| "Patients with measurable metastasis foci (n=111) were enrolled, and 108 patients were regarded as eligible." | 2.71 | A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. ( Aoyama, H; Horikoshi, N; Kimura, M; Miura, S; Morimoto, K; Noguchi, S; Ota, J; Saek, T; Sano, M; Shimizu, S; Taguchi, T; Takashima, S, 2004) |
| "The incidence of breast cancer increases with age." | 2.71 | A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer. ( Fleming, GF; Gupta, S; Mauer, AM; Ryan, CW; Samuels, BL; Taber, DA, 2005) |
| " Pharmacokinetic parameters of plasma 5-FU were as follows: Cmax, 128." | 2.69 | Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. ( Aiba, K; Denno, R; Hirata, K; Horikoshi, N; Ishizuka, H; Nakano, Y; Okazaki, M; Sasaki, K; Shirasaka, T; Taguchi, T; Uno, S; Yamada, Y, 1999) |
| " The removal of one administration of vinorelbine at dose levels 3 and 4 has allowed for increased UFT dosage and AUC0-6 h of fluorouracil, with no dose-limiting toxicity reported for these patients." | 2.69 | UFT/leucovorin plus vinorelbine combination for advanced breast cancer. ( Bonneterre, J; Déporte, R; Fargeot, P; Fumoleau, P; Kerbrat, P, 2000) |
| " Trials of new combinations are warranted to take advantage of the pharmacokinetic properties and oral bioavailability of UFT and leucovorin." | 2.68 | Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; Garcia Alfonso, P; Garcia Girón, C; Garrido, P; González Barón, M; Jara, C; Ruiz, A; Vincent, JM; Zamora, P, 1997) |
| "Of these, 44 patients had bilateral breast cancer prior to initiation of adjuvant therapy (prechemotherapy) and 17 patients developed primary breast cancer on the contralateral side during or after completion of adjuvant therapy (postchemotherapy)." | 2.66 | Bilateral primary breast cancer in patients treated with adjuvant therapy. ( Berté, E; Buzdar, AU; Hortobagyi, GN; Smith, TL, 1988) |
| "According to the Japan Mammary Cancer Society's criteria of response, more than partial response was observed in 11 out of 32 cases (34." | 2.65 | [Clinical trial of UFT against disseminated breast cancer]. ( Harauchi, D; Itoh, S; Konishi, Y; Shinoto, M, 1984) |
| "UFT (tegafur and uracil) is an oral anticancer drug that has been developed in Japan." | 2.44 | UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction. ( Tanaka, F, 2007) |
| "The main therapy for primary breast cancer is not surgery, but a systemic therapy involving administration of cytotoxic chemotherapy or the use of ablative or additive endocrine therapy to control disseminated micrometastasis." | 2.40 | [Benefits of adjuvant chemotherapy for breast cancer]. ( Inaji, H; Koyama, H; Motomura, K; Noguchi, S, 1997) |
| " The issues under investigation include best chemotherapy dosage and duration, identification of risk factors and the role of preoperative chemotherapy." | 2.39 | ["State of the art" of adjuvant chemo-endocrine therapy for breast cancer in Japan]. ( Ikeda, T, 1994) |
| "Locally advanced breast cancer sometimes results in a large chest wall defect at mastectomy." | 1.62 | Skin grafting utilizing a skin of lateral thoracic area for chest wall reconstruction in patient who underwent mastectomy for locally advanced breast cancer. ( Fukuma, E; Haruyama, Y; Koshida, Y; Nakagawa, M; Nashimoto, M; Sakamoto, N, 2021) |
| "Metaplastic squamous cell carcinoma(MSCC)of the breast is very unusual and is histologically characterized by rapid progression." | 1.51 | [A Case of Metaplastic Squamous Cell Carcinoma of the Breast Successfully Treated with S-1]. ( Ando, S; Kamei, R; Kitamura, Y; Nabeya, M; Sakamoto, K; Tokuhisa, A; Yamamoto, T, 2019) |
| " S-1 monotherapy was relatively effective and safe in the treatment of advanced breast cancer in elderly patients." | 1.48 | Clinical efficacy and safety of S-1 monotherapy in the treatment of advanced breast cancer in elderly patients. ( Cui, S; Sun, Y; Ye, M; You, D; Zhao, Q, 2018) |
| "The tumor was diagnosed as breast carcinoma using a core needle biopsy." | 1.43 | [A Case of Primary Acinic Cell Carcinoma(ACC)of the Breast]. ( Iga, N; Ikeda, H; Ishizaki, M; Kawai, H; Nishi, H; Sugimoto, R; Waki, N; Yamashita, K; Yoshida, R, 2016) |
| " S-1 was shown to be effective and safe in Japanese metastatic breast cancer patients treated with previous chemotherapy, including anthracyclines." | 1.42 | Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study. ( Hirokawa, E; Kanbayashi, C; Nakamiya, N; Osaki, A; Saeki, T; Sano, H; Sato, N; Sekine, H; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S, 2015) |
| "The treatment efficacy of advanced breast cancer is still not promising." | 1.42 | Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study. ( Chen, Y; Han, C; Jiao, S; Li, J; Linghu, R; Si, W; Yang, B; Yang, J; You, J; Zhang, X; Zhu, Y, 2015) |
| "Peritoneal metastasis of breast cancer was suspected, and an operation was performed for a definitive diagnosis." | 1.42 | [A Case of Peritoneal Metastasis of Breast Cancer Diagnosed by Laparoscopic-Assisted Right Hemicolectomy]. ( Egawa, C; Goto, T; Hashimoto, T; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kimura, K; Kusama, H; Matsushita, K; Morimoto, Y; Motoyama, Y; Murakami, K; Nagano, T; Naito, A; Nakatsuka, S; Nitta, K; Ohmura, Y; Ohneda, Y; Okishiro, M; Sakisaka, H; Sato, Y; Takatsuka, Y; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H, 2015) |
| "Study subjects are all of metastatic breast cancer patients who are requested by their doctors to participate in these two trials." | 1.40 | Prospective cohort study: whether or not patients benefit from participation itself in randomized-controlled trials (SELECT BC ECO). ( Mukai, H; Ohashi, Y; Ohno, S, 2014) |
| "We report a rare case in which primary squamous cell carcinoma of the nipple skin was successfully treated with S-1 alone." | 1.40 | [A case of squamous cell carcinoma of the nipple skin successfully treated with S-1 alone]. ( Ishikawa, M; Miyoshi, K; Murakami, S; Nakano, R; Ohuchi, K; Sozaki, M; Uchiyama, A; Umeda, S, 2014) |
| " Adverse events were observed in 27 patients(77%), and adverse events of Grade >3 were observed in 7 patients(20%)." | 1.40 | [Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer - an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)]. ( Hayashi, K; Iwase, H; Kawano, I; Kuramoto, M; Nishimura, R; Tanigawa, T; Yamamoto, Y; Yamamoto-Ibusuki, M, 2014) |
| "She was diagnosed with breast cancer with multiple bone metastases including cervical vertebrae." | 1.40 | [Long-term control of stage IV breast and gastric cancer with combination therapy of S-1 and paclitaxel]. ( Fujita, Y; Ishikawa, F; Ito, H; Kamata, S; Nitta, H; Omoto, H; Yamada, C, 2014) |
| "The pathological diagnosis revealed squamous cell carcinoma of the left breast(pT3N1M0, Stage III A)." | 1.38 | [A resected case of complete response after treatment with S-1 for recurrent squamous cell carcinoma component of the breast]. ( Arihiro, K; Emi, A; Haruta, R; Kadoya, T; Kajitani, K; Kanno, E; Kataoka, T; Kobayashi, Y; Masumoto, N; Okada, M; Sasada, T; Shigematsu, H, 2012) |
| " We examined 1361 patients between January 2006 and December 2007 with regard to the incidence of adverse drug reactions graded by the Common Terminology Criteria for Adverse Events (CTCAE), version 3." | 1.37 | Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab. ( Okamura, T; Oshitanai, R; Saito, Y; Suzuki, Y; Terada, M; Terao, M; Tokuda, Y; Tsuda, B, 2011) |
| "No distant recurrence was noted during this time." | 1.37 | [A case of breast cancer with postoperative metastasis to the supraclavicular lymph nodes-recurrence-free survival achieved by surgical excision following chemotherapy]. ( Dan, N; Hori, T; Nishino, H; Tendo, M; Tezuka, K, 2011) |
| "When treating advanced and metastatic breast cancer patients with chemotherapy, it is mandatory to maintain the patients quality of life while keeping an acceptable level of antitumor activity." | 1.37 | [Chemotherapy of a 2-week S-1 administration followed by 1-week rest for advanced and metastatic breast cancer]. ( Akizuki, M; Fujii, K; Fukutomi, T; Kobayashi, K; Kosaka, J; Mouri, Y; Nakano, S; Yorozuya, K; Yoshida, M, 2011) |
| "We report a case of breast carcinoma with repeated recurrences in the right bone." | 1.37 | [A case of repeated bone metastases of breast carcinoma successfully treated by S-1 chemotherapy]. ( Kinoshita, S; Kyoda, S; Morikawa, T; Okamoto, T; Takeyama, H; Uchida, K; Yamashita, A, 2011) |
| "We experienced 3 cases of recurrent breast cancer treated with S-1 therapy, delaying tumor progression and improving their quality of life (QOL)." | 1.36 | [Three cases of metastatic breast cancer effectively treated with S-1 therapy]. ( Kaisaki, S; Kato, M; Kitayama, J; Nagawa, H; Sanuki, J; Yamaguchi, H, 2010) |
| " In view of the side effects such as reduction in appetite and leukocyte, the dosage has been reduced as of the second course of treatment." | 1.36 | [A case of breast cancer with multiple hepatic metastasis successfully treated with S-1/PTX and S-1 chemotherapy]. ( Fujikuni, N; Hashimoto, M; Iwako, H; Kuranishi, F; Kuroda, Y; Moriyuki, T; Niitsu, H, 2010) |
| "We present here a case of interstitial pneumonitis that occurred after S-1 treatment." | 1.36 | [A case of interstitial pneumonitis induced by S-1]. ( Kanematsu, S; Kasahara, N; Kwon, AH; Nakatake, R; Okukawa, H; Shoji, T; Tanaka, K; Ueyama, Y; Yamamoto, D; Yoshida, H, 2010) |
| "We here describe a case of advanced breast cancer (Stage IV) in which an oral S-1+TAM therapy following a primary systemic chemo-radiotherapy has been effective in maintaining the patient's QOL." | 1.35 | [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)]. ( Enomoto, T; Hayashi, K; Iizuka, M; Kuranami, M; Nakakuma, T; Sengoku, N; Watanabe, M; Yoshimura, N, 2008) |
| "For treatment of recurrent breast carcinoma, S-1 is considered to be a useful and tolerable anticancer drug, and combination treatment of S-1 and ZOL is thought to be effective." | 1.35 | [A case of recurrent breast carcinoma metastasis successfully treated with S-1 and zoledronic acid therapy]. ( Arita, K; Hiranuma, S; Kuramochi, J; Kurokawa, T; Matsumoto, A; Sanada, K; Takiguchi, N; Tanaka, Y; Usui, S, 2009) |
| "We diagnosed her case to be bilateral breast cancer with peritonitis carcinomatosa, lymph node metastases and bony metastases." | 1.35 | [A case of bilateral breast cancer and metastatic gastric cancer with peritonitis carcinomatosa successfully treated with a combination therapy of S-1 and paclitaxel]. ( Aramaki, N; Iizuka, M; Kuranami, M; Kurita, A; Miyauchi, K; Nakakuma, T; Sengoku, N; Shiozawa, K; Ueno, S, 2009) |
| "The diagnosis was made as right breast cancer (T4c, N3c, M1, and stage IV)." | 1.35 | [A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies]. ( Aoyagi, H; Hamada, S; Kaneko, J; Katsuta, E; Maejima, S; Makinose, T; Okubo, K; Saguchi, M; Sato, T; Sekine, T; Someno, Y; Sugihara, K, 2009) |
| "A resected case of squamous cell carcinoma associated with ductal carcinoma in the hemilateral breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases is reported with some discussion." | 1.34 | [A resected case of squamous cell carcinoma of the breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases]. ( Akagawa, T; Fujioka, S; Hara, T; Hiramatsu, K; Hirata, A; Ito, T; Kato, K; Kutsuna, Y; Machiki, Y; Matsuba, H; Miyata, T, 2007) |
| "She was diagnosed as primary gastric cancer with peritoneal dissemination and received systemic chemotherapy after distal gastrectomy for a primary lesion." | 1.34 | [A case of breast metastasis of gastric cancer]. ( Cho, H; Hasegawa, S; Kobayashi, O; Osaragi, T; Sairenji, M; Tsuburaya, A; Yoshida, T; Yoshikawa, T, 2007) |
| "We report a case of advanced breast cancer (T4b, N3c, M1) achieving a significant improvement on QOL by multi-disciplinary therapy and S-1 administration." | 1.34 | [A case of advanced breast cancer successfully treated with multi-disciplinary therapy and S-1 administration]. ( Amano, S; Enomoto, K; Kitajima, A; Sakurai, K; Tani, M, 2007) |
| " Because salvage therapy with S-1 alone showed good antitumor efficacy and beneficial tolerability when the standard dosage was maintained, it was considered that this home therapy was effective for advanced/recurrent breast cancer that was resistant to anthracycline and taxane antitumor drugs." | 1.33 | [Effective salvage chemotherapy with S-1 alone in a patient with lung metastasis of breast cancer]. ( Itoh, K; Minami, H, 2005) |
| "We experienced a case of recurrent breast cancer resistant to prior medications, which was treated with oral S-1, a fluoropyrimidine-class anticancer drug, and exhibited the marked shrinkage of liver metastasis." | 1.33 | [A case of liver metastasis successfully treated with S-1 monotherapy in the patient with recurrent breast cancer]. ( Mitsuyama, S; Nishihara, K, 2006) |
| "In vivo experiments were performed on breast cancer xenografts to examine whether the combination therapy with S-1, an oral dihydrouracil dehydrogenase (DPD) inhibitory fluoropyrimidine, plus docetaxel functions as an additive/synergistic modulator in tumor growth." | 1.33 | Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice. ( Fukushima, M; Ikeda, T; Kitajima, M; Kubota, T; Ohmiya, H; Suto, A; Takeshita, T, 2006) |
| "S-1 could be a valuable agent for breast cancer treatments, since it showed clinical efficacy and mild toxicity, and can be given orally." | 1.33 | S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer. ( Aogi, K; Doihara, H; Nishimura, R; Ohsumi, S; Saeki, T; Taira, N; Takashima, S, 2006) |
| "We report a case of advanced breast cancer with meningeal metastasis and orbital metastasis (T4bN3cM1, Stage IV) achieving a significant improvement in QOL by multi-disciplinary therapy." | 1.33 | [A case of advanced breast cancer with meningeal carcinomas and orbital metastasis successfully treated with multi-disciplinary therapy]. ( Amano, S; Enomoto, K; Matsuo, S; Sakurai, K, 2006) |
| "One of the breast cancer patients introduced here suffered from recurrent carcinomatous pleurisy and the other from recurrent carcinomatous peritonitis." | 1.31 | [Improved QOL with cancer chemotherapy in two patients with breast cancer suffering form carcinomatous pleurisy and carcinomatous peritonitis]. ( Fujitomi, Y; Fujiyoshi, K; Yasue, K, 2000) |
| "To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice." | 1.31 | [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]. ( Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002) |
| "The mean PyNPase activity of primary breast cancer, assayed by ELISA method, was 140." | 1.30 | [Prognostic effect of PyNPase (pyrimidine nucleoside phosphorylase) activity in breast cancer]. ( Baba, K; Fukuda, M; Higuchi, A; Masuyama, S; Matsuda, M; Matsumoto, H; Matsuoka, Y; Miyayama, H; Nagao, K; Nishimura, R; Uchino, S; Yamashita, H, 1998) |
| "We recently established a metastasis model in nude mice using the MKL-4 cell line, a contransfectant of the MCF-7 human breast cancer cell line with fgf-4 and lacZ in which micrometastases in several organs can be quantitatively observed." | 1.30 | Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. ( Dickson, RB; Fujioka, A; Fukumori, H; Kurebayashi, J; Kurosumi, M; Nukatsuka, M; Saito, H; Sonoo, H; Takeda, S; Unemi, N, 1997) |
| "Multiple liver and lung metastasis of breast cancer were diagnosed because of high CA 15/3 serum levels and normal gastrointestinal study." | 1.30 | [Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report]. ( Hoshino, K; Ikeda, H; Koyama, T; Morishita, Y; Nakamura, M, 1999) |
| " A comparison of the prescribed dosage and patient records revealed a mean dose rate of 86." | 1.30 | [UFT-E granule compliance in postoperative adjuvant chemotherapy]. ( Hagiwara, M; Hanai, A; Kanasugi, K; Komoriyama, H; Yamaguchi, S, 1999) |
| "We recently established a spontaneous metastasis model of MKL-4 human breast cancer cells transplanted into nude mice." | 1.29 | [Antiproliferative and antimetastatic effects of UFT on MKL-4 human breast cancer cells transplanted into nude mice]. ( Kurebayashi, J; Sonoo, H, 1995) |
| "Peritoneal metastasis of breast cancer was one of the worst reactions with any therapy." | 1.29 | [A case of peritoneal metastasis of breast cancer successfully treated by multidisciplinary therapy with hyperthermia therapy]. ( Arima, M; Ebihara, Y; Kimura, K; Koyanagi, Y; Kusama, M; Matsunaga, T; Murata, A; Nakamura, Y; Shimizu, T, 1994) |
| "Evaluability of gastric and breast cancers was very low because of the poor growth of the grafts irrespective of the immunity of host animals." | 1.29 | [Evaluation of subrenal capsule assay (SRC) for clinical cancers]. ( Akao, S; Ishikawa, H; Iwami, N; Kiumi, F; Oya, M; Sasaki, K; Terada, H, 1996) |
| "A 66-year-old woman with left breast cancer (medullary carcinoma; T1cN1M0; Stage II A) was treated with breast conserving therapy combined with lumpectomy, radiotherapy, chemotherapy and endocrine therapy beginning in March, 1990." | 1.28 | [A case report of bone metastasis diagnosed by MRI and effectively treated with UFT after breast conserving therapy for breast cancer]. ( Hamada, N; Inomata, T; Nishioka, A; Ogawa, Y; Ogoshi, S; Sawada, A; Tanaka, Y; Terashima, M, 1992) |
| "Tamoxifen and UFT were administered as chemoendocrine therapy." | 1.28 | [A case of brain metastasis from breast cancer responding to chemoendocrine therapy]. ( Abe, R; Honda, K; Kanazawa, M; Nomizu, T; Tsuchiya, A; Watanabe, F; Yamaki, Y, 1990) |
| "A Case of local recurrent breast cancer in a 45-year-old female with complete response to Combination of chemotherapy and topical administration of Adriamycin is reported." | 1.28 | [A case of local recurrent breast cancer with complete response to combination of systemic chemotherapy and topical use of adriamycin ointment]. ( Deguchi, S; Hokama, A; Kurihara, K; Muto, Y; Nomura, K; Toda, T, 1990) |
| "From 1976 to 1984, 135 recurrent breast cancer patients were treated with chemotherapy and/or additive endocrine therapy and their initial therapies and survival time were analyzed." | 1.28 | Impact of initial therapy on survival in recurrent breast cancer. ( Iwanaga, T; Koyama, H; Nishizawa, Y; Noguchi, S; Shiba, E; Terasawa, T, 1989) |
| "Thirty postoperative patients with breast cancer (stage I, II) were studied to clarify the changes of peripheral lymphocyte subsets by administration of anticancer drugs (UFT, cyclophosphamide (CPM]." | 1.28 | [Changes in lymphocyte subsets with post-operative chemotherapy in breast carcinoma--a study of using two color analysis]. ( Kimura, M; Koida, T, 1989) |
| "Twenty-eight patients with a metastatic breast cancer who have achieved a complete remission from a combination chemotherapy that included doxorubicin have been analyzed to ascertain the factors which affect the duration of the response and the survival time." | 1.28 | [A study of complete responders in cases of metastatic breast cancer treated with combination chemotherapy]. ( Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Mizunuma, N; Mukaiyama, T; Ogawa, M; Shinagawa, K; Tabata, M, 1989) |
| "In 41 cases of primary breast cancer preoperative treatment was performed using 2 methods consisting CPA + FT-207 (5-FUDS) (for Group I) and CPA + FT-207 (5-FUDS) + MMC (for Group II) to determine clinical and histological efficacies." | 1.27 | [Clinical study on preoperative chemotherapy of primary breast cancer. 2--A comparative study of CPA + FT-207 (5-FUDS) and CPA + FT-207 (5-FUDS) + MMC]. ( Andoh, H; Fujii, Y; Gotoh, M; Hagiwara, H; Hara, Y; Kataoka, J; Kobayashi, T; Komuro, K; Nagasaki, Y; Nagayama, A; Nakamura, K; Nakamura, R, 1983) |
| "FT and 5-FU fractions in cancer tissues were found to be higher than those of the patients receiving only 800 mg of Tegafur fine granules as previously reported." | 1.27 | [UFT concentration in various tissues from cancer patients]. ( Bekki, E; Hashimoto, I; Kasai, Y; Mikami, J; Nakamura, T; Nakanishi, Y; Nishi, H; Nishindai, H; Sawada, Y; Yoshimoto, M, 1983) |
| "CR was observed in one case of breast cancer, and PR in 29 cases." | 1.27 | [Cooperative phase II study of spansule tegafur (SF-SP)]. ( Taguchi, T, 1984) |
| " In these 5 cases the daily dosage was 800 mg, and the median duration of PR was 51 days." | 1.27 | [Study of chemotherapy in the field of internal medicine--clinical experience with SF-SP]. ( Fujisawa, T; Imamura, Y; Irie, K; Mizogami, H; Nakamura, T; Nishimura, S; Sawada, Y; Yasutake, K; Yoshida, M; Yoshimura, Y, 1986) |
| "A case of right breast and thyroid cancer is reported in which, despite metastasis to the spinal cord occurring 1 year after mastectomy, satisfactory therapeutic results were obtained." | 1.27 | [Complete remission in a case of concurrent breast and thyroid cancers with metastatic spinal paralysis]. ( Kure, M; Niwa, M; Ohganè, T, 1986) |
| "Eight had mammary cancer." | 1.27 | [Thymidylate synthase inhibition in malignant tumors after oral administration of UFT]. ( Fujii, S; Miyauchi, S; Seiro, T; Shirasaka, T; Yamamoto, M; Yamamura, M, 1986) |
| "There were PR cases in hepatoma and breast cancer also." | 1.27 | [Clinical results of treatment with the UFT fine granule preparation under cooperative study. Tokyo Cancer Chemotherapy Cooperative Study Group]. ( Futatsuki, K; Kamano, T; Komita, T; Watanabe, H, 1987) |
| " Total Ftorafur (FT) results using the same criteria from the UFT phase II study revealed, from a comparison of dosage and disease type, that UFT did not enhance FT side effects; rather, it markedly increases effectiveness." | 1.27 | [Report on nationwide pooled data and cohort investigation in UFT phase II study]. ( Kimura, K; Ota, K; Taguchi, T, 1987) |
| "A 51-year-old woman with breast cancer metastatic to the pleura was treated with intrapleural instillation of adriamycin after thoracentesis, and systemic administration of FEMP, with complete response for more than 11 months." | 1.27 | [A case of breast cancer with pleural metastasis responding to administration of intrapleural adriamycin and systemic chemotherapy with FEMP]. ( Adachi, Y; Bada, K; Denno, R; Kohno, Y; Nishizawa, F; Ogasahara, K; Ohbayashi, M; Takahashi, J; Takeda, R; Yoshimura, T, 1987) |
| "In 16 patients with breast cancer who were administered UFT or FT-207 (UFT: 9 cases, FT-207: 7 cases) for a were prior to surgery, we studied the concentrations of 5-FU in the blood and tumor tissues, and in normal and metastatic lymph nodes sampled during surgery." | 1.27 | [5-FU concentration in the tissues (tumor and lymph node) of breast cancer patients given preoperative administration of UFT and FT]. ( Kimura, M; Koida, T, 1985) |
| "A case of toxic leucoencephalopathy induced by 5 FU derivatives is reported." | 1.27 | [A case of toxic leucoencephalopathy induced by 5FU derivatives]. ( Ishijima, B; Mizutani, T; Morimatsu, Y; Sato, J; Yasue, M, 1985) |
| "In twenty-nine cases of primary breast cancer preoperative treatment using CPA and FT-207 (or 5-FUDS) was performed to determine their efficacy." | 1.26 | [Clinical study of preoperative chemotherapy of primary breast cancer. 1. Efficacy of a combined use of CPA (endoxan) and FT-207 (or 5-FU dry syrup)]. ( Amano, R; Ando, H; Fujii, Y; Hara, Y; Hashiguchi, F; Komuro, K; Kurata, T; Nakamura, K; Nakamura, R; Sakamoto, R; Shimada, A; Yamazaki, M, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 76 (25.00) | 18.7374 |
| 1990's | 68 (22.37) | 18.2507 |
| 2000's | 72 (23.68) | 29.6817 |
| 2010's | 79 (25.99) | 24.3611 |
| 2020's | 9 (2.96) | 2.80 |
| Authors | Studies |
|---|---|
| Mukai, H | 13 |
| Uemura, Y | 5 |
| Akabane, H | 3 |
| Watanabe, T | 14 |
| Park, Y | 3 |
| Takahashi, M | 2 |
| Sagara, Y | 8 |
| Nishimura, R | 8 |
| Takashima, T | 10 |
| Fujisawa, T | 2 |
| Hozumi, Y | 6 |
| Kawahara, T | 6 |
| Muñoz, R | 2 |
| Hileeto, D | 1 |
| Cruz-Muñoz, W | 1 |
| Wood, GA | 1 |
| Xu, P | 1 |
| Man, S | 2 |
| Viloria-Petit, A | 1 |
| Kerbel, RS | 2 |
| Yamamoto, T | 1 |
| Nabeya, M | 1 |
| Tokuhisa, A | 1 |
| Kamei, R | 1 |
| Sakamoto, K | 1 |
| Kitamura, Y | 1 |
| Ando, S | 1 |
| Murata, T | 2 |
| Suzukamo, Y | 1 |
| Shiroiwa, T | 5 |
| Taira, N | 5 |
| Shimozuma, K | 8 |
| Ohashi, Y | 14 |
| Tanaka, T | 2 |
| Tanaka, M | 2 |
| Furusawa, H | 1 |
| Kamada, Y | 1 |
| Anan, K | 1 |
| Miyara, K | 1 |
| Kai, Y | 2 |
| Uga, T | 1 |
| Tamura, K | 1 |
| Mitsuyama, S | 4 |
| Sakamoto, N | 1 |
| Nashimoto, M | 1 |
| Nakagawa, M | 2 |
| Haruyama, Y | 1 |
| Koshida, Y | 2 |
| Fukuma, E | 3 |
| Ohno, S | 4 |
| Saji, S | 4 |
| Masuda, N | 5 |
| Tsuda, H | 4 |
| Akiyama, F | 2 |
| Kurosumi, M | 4 |
| Shimomura, A | 1 |
| Sato, N | 5 |
| Takao, S | 2 |
| Ohsumi, S | 5 |
| Tokuda, Y | 4 |
| Inaji, H | 7 |
| Toi, M | 5 |
| Imoto, S | 3 |
| Ishida, T | 3 |
| Ito, Y | 3 |
| Iwata, H | 3 |
| Shimizu, A | 1 |
| Ikeda, T | 6 |
| Haga, H | 1 |
| Saeki, T | 7 |
| Aogi, K | 4 |
| Sugie, T | 1 |
| Ueno, T | 2 |
| Kinoshita, T | 3 |
| Kitada, M | 1 |
| Sato, Y | 4 |
| Jimbo, K | 1 |
| Ishiguro, H | 2 |
| Takada, M | 1 |
| Yamamuro, M | 1 |
| Konishi, J | 1 |
| Nozaki, Y | 1 |
| Ueno, M | 1 |
| Kamo, N | 1 |
| Tanaka, N | 1 |
| Hara, F | 3 |
| Iwamoto, T | 1 |
| Yotsumoto, D | 2 |
| Saito, T | 3 |
| Watanabe, KI | 1 |
| Tsurutani, J | 5 |
| Toyama, T | 2 |
| Miki, M | 1 |
| Konishi, M | 1 |
| Shigeoka, Y | 1 |
| Miyashita, M | 1 |
| Suwa, H | 2 |
| Miyoshi, Y | 4 |
| Hirokaga, K | 1 |
| Okuno, T | 1 |
| Yamagami, K | 1 |
| Imamura, M | 1 |
| Murase, K | 1 |
| Yanai, A | 1 |
| Tanino, H | 1 |
| Kwakman, JJM | 1 |
| Baars, A | 1 |
| van Zweeden, AA | 1 |
| de Mol, P | 1 |
| Koopman, M | 1 |
| Kok, WEM | 1 |
| Punt, CJA | 1 |
| Hagiwara, Y | 5 |
| Imi, K | 1 |
| Isaka, H | 1 |
| Watanabe, K | 1 |
| Matsuyama, Y | 1 |
| Fukuda, T | 5 |
| Mouri, M | 2 |
| Fujii, T | 2 |
| Horiguchi, J | 2 |
| Yanagita, Y | 1 |
| Koibuchi, Y | 1 |
| Ikeda, F | 1 |
| Uchida, N | 1 |
| Kimura, M | 8 |
| Mugitani, T | 1 |
| Hatakeyama, T | 1 |
| Sakai, T | 1 |
| Matsumura, A | 1 |
| Ogino, S | 1 |
| Akami, T | 1 |
| Okano, S | 1 |
| Nakayama, T | 4 |
| Matsunami, N | 1 |
| Taguchi, T | 23 |
| Aono, T | 1 |
| Ito, T | 6 |
| Kagimura, T | 1 |
| Noguchi, S | 13 |
| Cui, S | 1 |
| Zhao, Q | 1 |
| Ye, M | 1 |
| You, D | 1 |
| Sun, Y | 1 |
| Kojima, Y | 1 |
| Yoshie, R | 1 |
| Kawamoto, H | 1 |
| Shimo, A | 1 |
| Uejima, T | 1 |
| Iwatani, T | 1 |
| Motoyoshi, A | 1 |
| Kanemaki, Y | 1 |
| Boku, N | 1 |
| Tsugawa, K | 1 |
| Yamaguchi, A | 1 |
| Taji, T | 1 |
| Shimizu, H | 2 |
| Masai, Y | 1 |
| Narui, K | 1 |
| Yoshino, H | 2 |
| Doihara, H | 3 |
| Suto, A | 2 |
| Tamura, M | 2 |
| Morimoto, T | 3 |
| Zaha, H | 1 |
| Chishima, T | 1 |
| Ishikawa, T | 3 |
| Kaneko, M | 1 |
| Yamada, T | 3 |
| Suzuki, Y | 2 |
| Ogiya, R | 1 |
| Oshitanai, R | 2 |
| Terao, M | 2 |
| Terada, M | 2 |
| Morioka, T | 1 |
| Tsuda, B | 2 |
| Niikura, N | 1 |
| Okamura, T | 2 |
| Saito, Y | 3 |
| Tsuji, W | 1 |
| Tanaka, S | 2 |
| Takeuchi, M | 1 |
| Otsuka, H | 1 |
| Toh, U | 1 |
| Iwakuma, N | 1 |
| Takahashi, R | 1 |
| Mishima, M | 1 |
| Takenaka, M | 1 |
| Kakuma, T | 1 |
| Shirouzu, K | 1 |
| Okazaki, M | 3 |
| Okazaki, A | 1 |
| Sato, F | 1 |
| Watanabe, Y | 2 |
| Yamagishi, H | 2 |
| Takata, D | 1 |
| Rokutanda, N | 1 |
| Nagaoka, R | 1 |
| Tokiniwa, H | 1 |
| Odawara, H | 1 |
| Kikuchi, M | 1 |
| Sato, A | 1 |
| Takeyoshi, I | 1 |
| Ishida, K | 1 |
| Moon, YW | 1 |
| Lee, S | 1 |
| Park, BW | 1 |
| Kim, EK | 1 |
| Kim, SI | 1 |
| Koo, JS | 1 |
| Park, S | 1 |
| Kim, MJ | 1 |
| Chung, HC | 1 |
| Kim, JH | 1 |
| Sohn, J | 1 |
| Enomoto, K | 5 |
| Sakurai, K | 4 |
| Yoshidome, K | 2 |
| Kawajiri, H | 2 |
| Kamigaki, S | 3 |
| Arai, T | 2 |
| Komoike, Y | 3 |
| Doi, T | 1 |
| Miyauchi, K | 3 |
| Sakamoto, J | 2 |
| Morita, S | 2 |
| Shien, T | 2 |
| Fukutomi, T | 2 |
| Inoue, K | 9 |
| Ando, J | 3 |
| Takashima, S | 9 |
| Nakamura, K | 3 |
| Shibata, T | 1 |
| Fukuda, H | 1 |
| Murakami, S | 3 |
| Umeda, S | 1 |
| Sozaki, M | 1 |
| Miyoshi, K | 1 |
| Ishikawa, M | 1 |
| Uchiyama, A | 1 |
| Ohuchi, K | 1 |
| Nakano, R | 1 |
| Yamamoto, Y | 2 |
| Tanigawa, T | 2 |
| Kawano, I | 1 |
| Hayashi, K | 3 |
| Kuramoto, M | 1 |
| Yamamoto-Ibusuki, M | 1 |
| Iwase, H | 1 |
| Ishizuna, K | 1 |
| Ninomiya, J | 1 |
| Ogawa, T | 2 |
| Kojima, M | 2 |
| Tsuji, E | 1 |
| Kawashima, M | 1 |
| Nozaki, M | 1 |
| Ueda, Y | 1 |
| Sakiyama, T | 1 |
| Iwasa, T | 2 |
| Kawakami, H | 1 |
| Nonagase, Y | 1 |
| Yoshida, T | 2 |
| Tanaka, K | 4 |
| Fujisaka, Y | 1 |
| Kurata, T | 2 |
| Nishio, K | 1 |
| Nakagawa, K | 3 |
| Yamada, C | 1 |
| Ishikawa, F | 1 |
| Nitta, H | 1 |
| Fujita, Y | 2 |
| Omoto, H | 1 |
| Kamata, S | 1 |
| Ito, H | 1 |
| Kuroi, K | 1 |
| Miyazaki, M | 1 |
| Nishina, S | 1 |
| Makimura, C | 1 |
| Tanizaki, J | 1 |
| Okamoto, K | 1 |
| Yamashita, T | 1 |
| Aruga, T | 1 |
| Shigekawa, T | 2 |
| Yamamoto, D | 4 |
| Iwase, S | 2 |
| Tsubota, Y | 1 |
| Ariyoshi, K | 1 |
| Kawaguchi, T | 2 |
| Miyaji, T | 1 |
| Sueoka, N | 1 |
| Yamamoto, C | 2 |
| Teramoto, S | 1 |
| Odagiri, H | 2 |
| Kitamura, K | 2 |
| Nagumo, Y | 2 |
| Yamaguchi, T | 1 |
| Osaki, A | 2 |
| Sekine, H | 1 |
| Kanbayashi, C | 1 |
| Sano, H | 1 |
| Takeuchi, H | 1 |
| Ueda, S | 1 |
| Nakamiya, N | 1 |
| Sugitani, I | 1 |
| Sugiyama, M | 1 |
| Shimada, H | 1 |
| Hirokawa, E | 1 |
| Takahashi, T | 1 |
| Nakayama, I | 1 |
| Muranishi, Y | 1 |
| Li, J | 1 |
| You, J | 1 |
| Si, W | 1 |
| Zhu, Y | 1 |
| Chen, Y | 1 |
| Yang, B | 1 |
| Han, C | 1 |
| Linghu, R | 1 |
| Zhang, X | 1 |
| Jiao, S | 1 |
| Yang, J | 1 |
| Martin, M | 4 |
| Lopez-Tarruella, S | 1 |
| Matsubara, N | 1 |
| Takano, T | 1 |
| Okishiro, M | 1 |
| Ohneda, Y | 1 |
| Motoyama, Y | 1 |
| Morimoto, Y | 1 |
| Kusama, H | 1 |
| Matsushita, K | 2 |
| Hashimoto, T | 1 |
| Kimura, K | 4 |
| Naito, A | 1 |
| Murakami, K | 1 |
| Katsura, Y | 1 |
| Nitta, K | 1 |
| Ohmura, Y | 1 |
| Kagawa, Y | 1 |
| Takeno, A | 1 |
| Sakisaka, H | 1 |
| Taniguchi, H | 1 |
| Egawa, C | 1 |
| Takeda, Y | 1 |
| Kato, T | 1 |
| Tamura, S | 1 |
| Takatsuka, Y | 2 |
| Goto, T | 2 |
| Nagano, T | 1 |
| Nakatsuka, S | 1 |
| Kashiwaba, M | 1 |
| Iwamoto, M | 2 |
| Takahashi, Y | 2 |
| Fujioka, H | 1 |
| Terasawa, R | 1 |
| Kawaguchi, K | 1 |
| Ikari, A | 1 |
| Tominaga, T | 3 |
| Maezawa, S | 1 |
| Umezaki, N | 1 |
| Matsuda, J | 1 |
| Uchiyama, K | 1 |
| Kawai, H | 1 |
| Sugimoto, R | 1 |
| Iga, N | 1 |
| Ikeda, H | 2 |
| Yoshida, R | 1 |
| Waki, N | 1 |
| Ishizaki, M | 1 |
| Nishi, H | 2 |
| Yamashita, K | 1 |
| Shiba, E | 6 |
| Yamamoto, H | 2 |
| Takahara, S | 1 |
| Tokushima, H | 1 |
| Osaki, Y | 1 |
| Tokudome, N | 1 |
| Sugihara, T | 1 |
| Takahashi, S | 2 |
| Iwase, T | 1 |
| Hatake, K | 2 |
| Iizuka, M | 2 |
| Sengoku, N | 2 |
| Nakakuma, T | 2 |
| Yoshimura, N | 1 |
| Enomoto, T | 1 |
| Kuranami, M | 2 |
| Watanabe, M | 1 |
| Tanaka, Y | 2 |
| Kurokawa, T | 2 |
| Arita, K | 1 |
| Kuramochi, J | 1 |
| Usui, S | 1 |
| Matsumoto, A | 2 |
| Takiguchi, N | 1 |
| Hiranuma, S | 1 |
| Sanada, K | 1 |
| Sano, M | 6 |
| Kitaya, T | 1 |
| Yoshimoto, M | 3 |
| Kohno, N | 2 |
| Nakagami, K | 1 |
| Sonoo, H | 4 |
| Sakamoto, G | 2 |
| Tokugawa, T | 1 |
| Kobayashi, A | 2 |
| Okubo, K | 2 |
| Matsuyama, T | 1 |
| Imai, S | 1 |
| Koyama, H | 18 |
| Sakurai, T | 2 |
| Umemura, T | 1 |
| Jinta, E | 1 |
| Suzuma, T | 1 |
| Yoshimura, G | 2 |
| Shimizu, S | 3 |
| Okamura, K | 1 |
| Koh, J | 2 |
| Kyono, S | 1 |
| Higaki, K | 1 |
| Ogita, M | 2 |
| Asaga, T | 1 |
| Komichi, H | 1 |
| Yamazaki, K | 1 |
| Tanaka, F | 2 |
| Nishikawa, H | 1 |
| Suzuki, T | 4 |
| Miyamoto, Y | 1 |
| Abe, M | 2 |
| Hasuo, T | 1 |
| Doiguchi, M | 1 |
| Sakamoto, F | 1 |
| Coşkun, U | 1 |
| Kaya, AO | 1 |
| Alkis, N | 1 |
| Buyukberber, S | 1 |
| Alici, S | 1 |
| Celenkoglu, G | 1 |
| Uncu, D | 1 |
| Ozkan, M | 1 |
| Sevinc, A | 1 |
| Benekli, M | 1 |
| Ueno, S | 1 |
| Aramaki, N | 1 |
| Shiozawa, K | 1 |
| Kurita, A | 1 |
| Aoyagi, H | 2 |
| Kaneko, J | 2 |
| Makinose, T | 1 |
| Someno, Y | 2 |
| Katsuta, E | 2 |
| Saguchi, M | 2 |
| Hamada, S | 2 |
| Sekine, T | 1 |
| Sato, T | 3 |
| Sugihara, K | 1 |
| Maejima, S | 2 |
| Hortobagyi, GN | 5 |
| Heim, W | 1 |
| Hutchins, L | 1 |
| Rivera, E | 1 |
| Mason, B | 1 |
| Booser, DJ | 1 |
| Kirshner, J | 1 |
| Young, RR | 1 |
| Karwal, M | 1 |
| Ibrahim, NK | 1 |
| Hermann, R | 1 |
| Murray, JL | 1 |
| Watkins, SP | 1 |
| Gore, I | 1 |
| Ohmura, T | 1 |
| Yajima, T | 1 |
| Kato, M | 1 |
| Kitayama, J | 2 |
| Yamaguchi, H | 1 |
| Sanuki, J | 1 |
| Kaisaki, S | 1 |
| Nagawa, H | 1 |
| Fukui, T | 1 |
| Mitsudomi, T | 1 |
| Hashimoto, M | 1 |
| Moriyuki, T | 1 |
| Kuranishi, F | 1 |
| Niitsu, H | 1 |
| Fujikuni, N | 1 |
| Iwako, H | 1 |
| Kuroda, Y | 2 |
| Kubo, H | 1 |
| Kijima, D | 1 |
| Tada, K | 1 |
| Miyahara, M | 1 |
| Hasegawa, H | 2 |
| Mizuta, N | 2 |
| Sakaguchi, K | 2 |
| Mizuta, M | 2 |
| Ichida, M | 1 |
| Ohashi, M | 1 |
| Umeda, Y | 1 |
| Nishiyama, A | 1 |
| Matsumoto, M | 2 |
| Fujiwara, I | 2 |
| Miwa, H | 1 |
| Fukunaga, M | 1 |
| Ohsato, H | 1 |
| Imamura, H | 2 |
| Sohta, Y | 1 |
| Kaze, C | 1 |
| Furukawa, H | 1 |
| Ueyama, Y | 1 |
| Yoshida, H | 3 |
| Kanematsu, S | 2 |
| Nakatake, R | 1 |
| Kasahara, N | 1 |
| Shoji, T | 1 |
| Okukawa, H | 1 |
| Kwon, AH | 1 |
| Nukatsuka, M | 5 |
| Saito, H | 3 |
| Nakagawa, F | 4 |
| Uchida, J | 3 |
| Shibata, J | 1 |
| Matsuo, K | 1 |
| Kiniwa, M | 1 |
| Ah, K | 1 |
| Inoue, H | 1 |
| Yano, H | 1 |
| Shimabukuro, R | 1 |
| Shiraishi, T | 1 |
| Takahashi, I | 2 |
| Nishizaki, T | 1 |
| Murakami, M | 1 |
| Ohkubo, T | 1 |
| Takahata, T | 1 |
| Hasegawa, K | 1 |
| Kiyoto, S | 1 |
| Takabatake, D | 1 |
| Tazawa, K | 1 |
| Tsuchiya, Y | 1 |
| Shinbo, M | 1 |
| Yamagishi, F | 1 |
| Shimada, K | 1 |
| Matsui, K | 2 |
| Nagata, T | 1 |
| Shimada, Y | 1 |
| Tsukada, K | 1 |
| Yoneyama, K | 2 |
| Takeshita, T | 2 |
| Suzuki, H | 1 |
| Morise, M | 1 |
| Kishi, S | 1 |
| Tsutsui, A | 1 |
| Villanueva, C | 1 |
| Chaigneau, L | 1 |
| Dufresne, A | 1 |
| Thierry Vuillemin, A | 1 |
| Stein, U | 1 |
| Demarchi, M | 1 |
| Bazan, F | 1 |
| N'guyen, T | 1 |
| Pivot, X | 1 |
| Antón, A | 1 |
| Barnadas, A | 1 |
| Florián, J | 1 |
| Ribelles, N | 1 |
| Lomas, M | 1 |
| Lao, J | 1 |
| González-Quintás, A | 1 |
| Margelí, M | 1 |
| Paules, AB | 1 |
| Gayo, J | 1 |
| Ramos, M | 1 |
| Tamada, S | 1 |
| Baba, S | 1 |
| Matsukata, A | 1 |
| Andou, M | 1 |
| Rai, Y | 2 |
| Nakamoto, Y | 1 |
| Kayata, Y | 1 |
| Kikawa, Y | 1 |
| Ogata, M | 1 |
| Yamamoto, M | 2 |
| Nakajima, F | 1 |
| Matsuoka, K | 1 |
| Nomura, H | 1 |
| Araya, J | 1 |
| Tezuka, K | 1 |
| Dan, N | 1 |
| Tendo, M | 1 |
| Hori, T | 1 |
| Nishino, H | 1 |
| Fujii, K | 1 |
| Kosaka, J | 1 |
| Mouri, Y | 1 |
| Yoshida, M | 3 |
| Yorozuya, K | 1 |
| Nakano, S | 1 |
| Akizuki, M | 1 |
| Kobayashi, K | 1 |
| Mori, T | 3 |
| Ito, D | 1 |
| Furumoto, K | 1 |
| Kogire, M | 2 |
| Ferrero, JM | 1 |
| Largillier, R | 1 |
| Michel, C | 1 |
| Amiot, V | 1 |
| Milano, G | 1 |
| Hébert, C | 1 |
| Mari, V | 1 |
| Courdi, A | 1 |
| Figl, A | 1 |
| Follana, P | 1 |
| Barrière, J | 1 |
| Chamorey, E | 1 |
| Tamori, A | 1 |
| Motoyama, H | 1 |
| Morikawa, H | 1 |
| Enomoto, M | 1 |
| Hirakawa, K | 3 |
| Kawada, N | 1 |
| Takeyama, H | 1 |
| Kyoda, S | 1 |
| Yamashita, A | 1 |
| Kinoshita, S | 2 |
| Okamoto, T | 1 |
| Uchida, K | 1 |
| Morikawa, T | 1 |
| Kobayashi, Y | 1 |
| Kadoya, T | 1 |
| Kanno, E | 1 |
| Sasada, T | 1 |
| Kajitani, K | 1 |
| Emi, A | 1 |
| Shigematsu, H | 1 |
| Masumoto, N | 1 |
| Haruta, R | 2 |
| Kataoka, T | 2 |
| Arihiro, K | 1 |
| Okada, M | 1 |
| Morimoto, M | 1 |
| Tangoku, A | 1 |
| Shimizu, C | 2 |
| Galmarini, CM | 1 |
| Garbovesky, C | 1 |
| Galmarini, D | 1 |
| Galmarini, FC | 1 |
| Kasumi, F | 1 |
| Uchino, J | 5 |
| Abe, R | 6 |
| Nomura, Y | 4 |
| Sugimachi, K | 4 |
| Nakazato, H | 1 |
| Abe, O | 6 |
| Hata, Y | 3 |
| Takahashi, H | 1 |
| Todo, S | 1 |
| Asaishi, K | 3 |
| Hirata, K | 3 |
| Okushiba, S | 1 |
| Kato, H | 1 |
| Urien, S | 1 |
| Fumoleau, P | 3 |
| Campone, M | 1 |
| Kerbrat, P | 3 |
| Bonneterre, J | 2 |
| Fargeot, P | 2 |
| Deporte-Fety, R | 2 |
| Mayor, S | 1 |
| Nagao, K | 2 |
| Miyayama, H | 2 |
| Okazaki, S | 1 |
| Fujimura, Y | 1 |
| Nagasaki, E | 1 |
| Furuta, N | 1 |
| Shinozaki, E | 1 |
| Tokutome, N | 1 |
| Mishima, Y | 1 |
| Chin, K | 1 |
| Terui, Y | 1 |
| Mizunuma, N | 4 |
| Itoh, Y | 1 |
| Usui, N | 3 |
| Hartman, AR | 1 |
| Grekowicz, A | 1 |
| Lum, BL | 1 |
| Carlson, RW | 1 |
| Schurman, C | 1 |
| Sikic, BI | 1 |
| Shapiro, R | 1 |
| Stockdale, FE | 1 |
| Arikawa, R | 1 |
| Kanekura, T | 1 |
| Uchimiya, H | 1 |
| Kanzaki, T | 1 |
| Horikoshi, N | 12 |
| Miura, S | 3 |
| Morimoto, K | 3 |
| Watanabe, O | 1 |
| Shimizu, T | 2 |
| Kinoshita, J | 1 |
| Okabe, T | 1 |
| Ogawa, K | 1 |
| Haga, S | 1 |
| Hashimoto, K | 2 |
| Nio, Y | 2 |
| Koike, M | 2 |
| Itakura, M | 2 |
| Yano, S | 1 |
| Higami, T | 1 |
| Fujioka, A | 4 |
| Oshimo, H | 1 |
| Kitazato, K | 2 |
| Sugimoto, Y | 1 |
| Nagayama, S | 1 |
| Fukushima, M | 5 |
| Saek, T | 1 |
| Aoyama, H | 2 |
| Ota, J | 2 |
| Gupta, S | 1 |
| Mauer, AM | 1 |
| Ryan, CW | 1 |
| Taber, DA | 1 |
| Samuels, BL | 1 |
| Fleming, GF | 1 |
| Akazawa, K | 1 |
| Takagaki, K | 1 |
| Ogawa, Y | 3 |
| Onoda, N | 2 |
| Nakata, B | 2 |
| Kato, Y | 2 |
| Itoh, K | 1 |
| Minami, H | 1 |
| Nishihara, K | 1 |
| Shaked, Y | 1 |
| Lee, CR | 1 |
| Wong, J | 1 |
| Francia, G | 1 |
| Kubota, T | 2 |
| Ohmiya, H | 1 |
| Kitajima, M | 1 |
| Nakajima, H | 1 |
| Nakatsukasa, K | 1 |
| Hachimine, Y | 1 |
| Sawai, K | 1 |
| Sakai, K | 3 |
| Oka, T | 2 |
| Ozawa, K | 1 |
| Senoo, T | 2 |
| Terasawa, T | 13 |
| Nakao, K | 2 |
| Oshima, A | 2 |
| Iguchi, C | 1 |
| Kodama, H | 1 |
| Toga, T | 1 |
| Maruyama, R | 1 |
| Amano, S | 2 |
| Matsuo, S | 1 |
| Hiramatsu, K | 1 |
| Kato, K | 2 |
| Hirata, A | 1 |
| Matsuba, H | 1 |
| Hara, T | 1 |
| Miyata, T | 1 |
| Akagawa, T | 1 |
| Kutsuna, Y | 1 |
| Machiki, Y | 1 |
| Fujioka, S | 1 |
| Hasegawa, S | 1 |
| Yoshikawa, T | 1 |
| Osaragi, T | 1 |
| Cho, H | 1 |
| Tsuburaya, A | 1 |
| Kobayashi, O | 1 |
| Sairenji, M | 1 |
| Yamada, A | 1 |
| Toriumi, F | 1 |
| Murayama, T | 1 |
| Toeda, H | 1 |
| Imazu, Y | 1 |
| Motegi, K | 1 |
| Akamatsu, H | 1 |
| Ooyama, R | 1 |
| Passardi, A | 1 |
| Maltoni, R | 1 |
| Milandri, C | 1 |
| Cecconetto, L | 1 |
| Massa, I | 1 |
| Zoli, W | 1 |
| Tesei, A | 1 |
| Fabbri, F | 1 |
| Nanni, O | 1 |
| Amadori, D | 1 |
| Kitajima, A | 1 |
| Tani, M | 1 |
| Akashi-Tanaka, S | 1 |
| Yonemori, K | 1 |
| Kohno, T | 1 |
| Hojo, T | 1 |
| Ando, M | 1 |
| Katsumata, N | 1 |
| Fujiwara, Y | 1 |
| Fujita, F | 4 |
| Fujita, M | 4 |
| Komuro, K | 2 |
| Hara, Y | 2 |
| Fujii, Y | 2 |
| Nagayama, A | 1 |
| Kobayashi, T | 3 |
| Gotoh, M | 1 |
| Hagiwara, H | 1 |
| Nakamura, R | 2 |
| Nagasaki, Y | 1 |
| Kataoka, J | 1 |
| Andoh, H | 1 |
| Hiraide, H | 1 |
| Mimura, K | 1 |
| Kawano, M | 1 |
| Hatsuse, K | 1 |
| Kadota, T | 1 |
| Tamaki, K | 1 |
| Kanabe, S | 1 |
| Mizoguchi, O | 1 |
| Terashima, H | 1 |
| Iwasa, H | 1 |
| Kasai, Y | 1 |
| Nakanishi, Y | 1 |
| Nishindai, H | 1 |
| Nakamura, T | 4 |
| Hashimoto, I | 1 |
| Sawada, Y | 2 |
| Mikami, J | 1 |
| Bekki, E | 1 |
| Wakui, A | 1 |
| Soejima, S | 1 |
| Kako, N | 1 |
| Kimura, Y | 1 |
| Soga, S | 1 |
| Nomura, S | 1 |
| Okouchi, Y | 1 |
| Ansfield, FJ | 1 |
| Kallas, GJ | 1 |
| Singson, JP | 1 |
| Ogawa, M | 9 |
| Inagaki, J | 4 |
| Miyamoto, H | 1 |
| Ikeda, K | 3 |
| Nakada, H | 2 |
| Adachi, K | 2 |
| Kumazawa, H | 1 |
| Imai, N | 1 |
| Shioya, M | 1 |
| Fukaya, Y | 1 |
| Noguchi, A | 1 |
| Yayoi, E | 1 |
| Maeura, Y | 1 |
| Tada, A | 2 |
| Yamazaki, H | 2 |
| Itoh, S | 1 |
| Konishi, Y | 1 |
| Harauchi, D | 1 |
| Shinoto, M | 1 |
| Wada, T | 7 |
| Nishizawa, Y | 6 |
| Fukuda, I | 1 |
| Iwanaga, T | 6 |
| Murosaki, S | 1 |
| Esaki, K | 1 |
| Nagura, E | 1 |
| Ueoka, H | 1 |
| Takano, Y | 1 |
| Okabe, K | 1 |
| Matthes, ML | 1 |
| Lenk, H | 1 |
| Gürtler, R | 1 |
| Tanneberger, S | 1 |
| Yamazaki, M | 1 |
| Amano, R | 1 |
| Hashiguchi, F | 1 |
| Sakamoto, R | 1 |
| Shimada, A | 1 |
| Ando, H | 1 |
| Suemasu, K | 1 |
| Nomoto, C | 1 |
| Higashi, Y | 1 |
| Numata, H | 1 |
| Sakamoto, H | 1 |
| Kurebayashi, J | 4 |
| Solé, LA | 1 |
| Albanell, J | 2 |
| Bellmunt, J | 2 |
| Ribas, A | 2 |
| Gallego, OS | 1 |
| Carulla, J | 2 |
| Yoshida, Y | 2 |
| Matsuda, R | 1 |
| Takatsuki, H | 1 |
| Shimahara, Y | 1 |
| Kobayashi, N | 1 |
| Kiman, K | 1 |
| Suzuki, S | 1 |
| Satomi, T | 1 |
| Sakonji, M | 1 |
| Nihei, M | 1 |
| Kimijima, I | 1 |
| Sasa, M | 1 |
| Monden, Y | 3 |
| Sakai, S | 1 |
| Kusama, M | 3 |
| Koyanagi, Y | 3 |
| Ebihara, Y | 1 |
| Arima, M | 1 |
| Murata, A | 1 |
| Nakamura, Y | 2 |
| Matsunaga, T | 2 |
| Tashiro, H | 1 |
| Ohsaki, A | 1 |
| Tsuchiya, A | 3 |
| Koie, H | 2 |
| Ono, K | 2 |
| Abo, S | 2 |
| Saito, K | 2 |
| Tsukamoto, M | 2 |
| Mori, S | 2 |
| Kikuchi, K | 2 |
| Samejima, N | 1 |
| Tanabe, T | 2 |
| Hayasaka, H | 1 |
| Mito, M | 2 |
| Takagi, H | 1 |
| Takeuchi, S | 1 |
| Nimura, Y | 1 |
| Mizumoto, R | 1 |
| Miyazaki, I | 2 |
| Kobayashi, S | 1 |
| Noguchi, M | 2 |
| Daniels, M | 1 |
| Díaz-Rubio, E | 3 |
| Guillem, V | 1 |
| Montero, JM | 1 |
| García-Conde, J | 1 |
| Estapé, J | 1 |
| Herranz, C | 1 |
| Ordoñez, A | 1 |
| Galán, A | 1 |
| Sakaguchi, T | 1 |
| Watahiki, Y | 1 |
| Kosaka, A | 2 |
| Kajanti, MJ | 1 |
| Pyrhönen, SO | 1 |
| Maiche, AG | 1 |
| Maruyama, S | 1 |
| Hirayama, C | 1 |
| Abe, J | 1 |
| Tanaka, J | 1 |
| Kosaki, G | 2 |
| Seno, T | 1 |
| Orita, K | 2 |
| Toge, T | 3 |
| Dohi, K | 3 |
| Ogawa, N | 2 |
| Akao, S | 1 |
| Iwami, N | 1 |
| Oya, M | 2 |
| Terada, H | 1 |
| Sasaki, K | 2 |
| Ishikawa, H | 1 |
| Kiumi, F | 1 |
| Villalon, AH | 1 |
| De Guzman, LM | 1 |
| Samson, MC | 1 |
| Guancia, AA | 1 |
| Fernando, GY | 1 |
| Romana, IB | 1 |
| Feliu, J | 1 |
| González Barón, M | 1 |
| Zamora, P | 1 |
| Garcia Alfonso, P | 1 |
| Garcia Girón, C | 1 |
| Blanco, E | 1 |
| Belón, J | 1 |
| Garrido, P | 1 |
| Jara, C | 1 |
| Ruiz, A | 1 |
| Vincent, JM | 1 |
| Espinosa, E | 1 |
| Tsukagoshi, S | 1 |
| Motomura, K | 1 |
| Casado, A | 2 |
| López-Martin, JA | 1 |
| Rodriguez-Lescure, A | 1 |
| Nieto, Y | 1 |
| Ayala, F | 1 |
| Iglesias, L | 1 |
| Moreno, JA | 1 |
| Torrija, E | 1 |
| Murillo, E | 1 |
| Codes, M | 1 |
| Dugue, A | 1 |
| Garcia, E | 1 |
| Virizuela, JA | 1 |
| Matsuda, M | 1 |
| Baba, K | 1 |
| Matsuoka, Y | 1 |
| Yamashita, H | 1 |
| Fukuda, M | 4 |
| Higuchi, A | 1 |
| Masuyama, S | 1 |
| Uchino, S | 1 |
| Matsumoto, H | 2 |
| Solé-Calvo, LA | 1 |
| Gallardo, E | 1 |
| Vera, R | 1 |
| Vidal, R | 1 |
| Baselga, J | 1 |
| Yamada, M | 1 |
| Tanemura, H | 1 |
| Oshita, H | 1 |
| Asano, M | 2 |
| Takeda, S | 3 |
| Unemi, N | 1 |
| Fukumori, H | 1 |
| Dickson, RB | 1 |
| Bunnell, CA | 1 |
| Winer, EP | 1 |
| Hoshino, K | 1 |
| Nakamura, M | 1 |
| Koyama, T | 1 |
| Morishita, Y | 1 |
| Yamaguchi, S | 4 |
| Ota, T | 1 |
| Nakayama, Y | 2 |
| Ogata, H | 2 |
| Shimizu, K | 2 |
| Nishikawa, T | 2 |
| Adachi, Y | 3 |
| Brito, RA | 1 |
| Medgyesy, D | 1 |
| Zukowski, TH | 1 |
| Royce, ME | 1 |
| Ravandi-Kashani, F | 1 |
| Hoff, PM | 1 |
| Pazdur, R | 1 |
| Dickson, NR | 1 |
| Nicholson, BP | 1 |
| Hande, K | 1 |
| Blanke, C | 1 |
| Johnson, D | 1 |
| Cohen, A | 1 |
| Klaassen, U | 1 |
| Borquez, D | 1 |
| Lang, S | 1 |
| Oberhoff, C | 1 |
| Harstrick, A | 1 |
| Seeber, S | 1 |
| Benner, S | 1 |
| Lück, HJ | 2 |
| Scholz, U | 2 |
| Kühnle, H | 2 |
| Dethling, J | 1 |
| Ohta, T | 1 |
| Smith, IE | 2 |
| Kubo, Y | 1 |
| Laguerre, B | 1 |
| Richardet, E | 1 |
| Pedraza, C | 1 |
| Mickiewicz, E | 1 |
| Lerzo, G | 1 |
| Bonamasa, M | 1 |
| Coppola, F | 1 |
| Elli, A | 1 |
| Uranga, G | 1 |
| Jovtis, S | 1 |
| Bruno, M | 1 |
| Ventriglia, M | 1 |
| Cuevas, MA | 1 |
| Alvarez, AM | 1 |
| Suarez, LA | 1 |
| Fein, L | 1 |
| Aoki, E | 1 |
| Aiba, K | 2 |
| Denno, R | 2 |
| Nakano, Y | 2 |
| Ishizuka, H | 1 |
| Yamada, Y | 6 |
| Uno, S | 1 |
| Shirasaka, T | 2 |
| Komoriyama, H | 2 |
| Hanai, A | 1 |
| Kanasugi, K | 2 |
| Hagiwara, M | 1 |
| Emi, Y | 1 |
| Nishijima, N | 1 |
| Kai, S | 1 |
| Kano, T | 1 |
| Palangié, T | 1 |
| Pierga, JY | 1 |
| Pouillart, P | 1 |
| Cilenti, G | 1 |
| Tozzi, L | 1 |
| Suriano, A | 1 |
| Tartarone, A | 1 |
| Lelli, G | 1 |
| Fujitomi, Y | 1 |
| Fujiyoshi, K | 1 |
| Yasue, K | 1 |
| Tamura, H | 1 |
| Kobayashi, H | 1 |
| Oka, S | 1 |
| Fujisaki, M | 1 |
| Wada, N | 1 |
| Kaise, H | 2 |
| Nakayama, S | 2 |
| Oota, D | 2 |
| Aoki, T | 2 |
| Asanuma, F | 2 |
| Kawamura, E | 2 |
| Canzler, U | 1 |
| Robner, D | 1 |
| Gregory, RK | 1 |
| Johnston, SR | 1 |
| Miles, D | 1 |
| Déporte, R | 1 |
| Ogisawa, K | 1 |
| Nagatsuka, I | 1 |
| Matsumura, Y | 1 |
| Yashiro, M | 1 |
| Lewis, NL | 1 |
| Meropol, NJ | 1 |
| Niiya, F | 1 |
| Ikeda, S | 1 |
| Nagata, S | 1 |
| Odou, E | 1 |
| Hayabuchi, N | 1 |
| Macias, JA | 1 |
| Garcia-Carbonero, I | 1 |
| Garcia-Saenz, JA | 1 |
| Oruezabal, M | 1 |
| Manrique, I | 1 |
| Sun, W | 1 |
| Haller, D | 1 |
| Cunningham, D | 1 |
| Coleman, R | 1 |
| Yamamoto, S | 1 |
| Kunisue, H | 1 |
| Otsuki, T | 1 |
| Ishihama, H | 1 |
| Ohshimo, H | 2 |
| Basaki, Y | 1 |
| Chikahisa, L | 1 |
| Aoyagi, K | 1 |
| Miyadera, K | 1 |
| Yonekura, K | 1 |
| Hashimoto, A | 1 |
| Okabe, S | 1 |
| Wierzba, K | 1 |
| Lichinitser, MR | 1 |
| Perevodchikova, NI | 1 |
| Garin, AM | 1 |
| Asserkritova, IV | 1 |
| Vaarik, GKh | 1 |
| Blokhina, NG | 1 |
| Smolianskaia, AZ | 2 |
| Aledseev, VM | 1 |
| Sokolova, VD | 1 |
| Romanenko, NV | 1 |
| Blumenschein, GR | 2 |
| Tashima, CK | 2 |
| Buzdar, AU | 3 |
| Burgess, MA | 1 |
| Livingston, RB | 1 |
| Valdivieso, M | 1 |
| Gutterman, JU | 2 |
| Hersh, EM | 1 |
| Bodey, GP | 2 |
| Yap, HY | 1 |
| Krutchik, AN | 1 |
| Benjamin, RS | 1 |
| Hattori, T | 2 |
| Akagi, M | 1 |
| Inokuchi, K | 1 |
| Hamada, Y | 1 |
| Nishioka, A | 1 |
| Hamada, N | 1 |
| Terashima, M | 1 |
| Sawada, A | 1 |
| Inomata, T | 1 |
| Ogoshi, S | 1 |
| Blomqvist, C | 1 |
| Tiusanen, K | 1 |
| Elomaa, I | 1 |
| Rissanen, P | 1 |
| Hietanen, T | 1 |
| Heinonen, E | 1 |
| Gröhn, P | 1 |
| Shibata, M | 1 |
| Saito, A | 1 |
| Hareyama, M | 1 |
| Morita, K | 1 |
| Mukaiyama, T | 5 |
| Itami, S | 1 |
| Hirano, A | 3 |
| Matsuoka, A | 1 |
| Matsumura, T | 1 |
| Fujiwara, K | 1 |
| Katoh, S | 1 |
| Kadota, K | 2 |
| Watatani, M | 1 |
| Houjou, T | 2 |
| Mori, N | 2 |
| Yasutomi, M | 1 |
| Josui, K | 1 |
| Ishibiki, K | 1 |
| Shiina, E | 1 |
| Aeba, S | 1 |
| Shiozaki, H | 1 |
| Ikeya, T | 1 |
| Maehara, M | 1 |
| Horiguchi, A | 1 |
| Kanou, T | 1 |
| Koibuchi, S | 1 |
| Shinkai, H | 1 |
| Oie, S | 1 |
| Takechi, T | 1 |
| Nakano, K | 2 |
| Tsukikawa, S | 1 |
| Imaki, S | 1 |
| Morikubo, M | 1 |
| Asakura, T | 1 |
| Okamura, R | 1 |
| Watanabe, H | 2 |
| Nomizu, T | 1 |
| Watanabe, F | 1 |
| Honda, K | 1 |
| Kanazawa, M | 1 |
| Yamaki, Y | 1 |
| Deguchi, S | 1 |
| Kurihara, K | 1 |
| Nomura, K | 1 |
| Hokama, A | 1 |
| Muto, Y | 1 |
| Toda, T | 1 |
| Kanda, K | 1 |
| Waki, S | 1 |
| Uchimura, M | 1 |
| Kida, H | 1 |
| Narita, K | 1 |
| Harada, N | 1 |
| Ueno, K | 1 |
| Endo, F | 1 |
| Ishii, T | 1 |
| Kito, T | 1 |
| Yasutake, K | 2 |
| Imamura, Y | 2 |
| Yoshimura, Y | 2 |
| Hozumi, T | 1 |
| Katou, J | 1 |
| Okutani, T | 1 |
| Irie, K | 2 |
| Koida, T | 3 |
| Wada, A | 2 |
| Yamamoto, A | 1 |
| Niimoto, M | 1 |
| Sumiyoshi, K | 1 |
| Matunami, N | 1 |
| Morikawa, E | 1 |
| Aizawa, M | 1 |
| Kurooka, K | 1 |
| Yamato, M | 1 |
| Matsumoto, S | 1 |
| Kutsuna, T | 1 |
| Tann, M | 1 |
| Mizuno, Y | 1 |
| Shinohara, M | 1 |
| Kimura, T | 1 |
| Banno, T | 1 |
| Yoshizaki, S | 1 |
| Shinagawa, K | 3 |
| Fukutani, H | 3 |
| Tabata, M | 2 |
| Kobayashi, R | 1 |
| Osada, T | 1 |
| Hamaguchi, M | 1 |
| Ohi, T | 1 |
| Inden, Y | 1 |
| Hara, K | 1 |
| Tomiyama, J | 1 |
| Tsukui, G | 1 |
| Kobori, O | 1 |
| Kousaki, G | 1 |
| Iwasa, Z | 1 |
| Utsunomiya, J | 1 |
| Okajima, K | 1 |
| Okamoto, E | 1 |
| Sakamoto, Y | 1 |
| Inaba, H | 1 |
| Adachi, I | 1 |
| Suzuki, M | 1 |
| Tsuchihashi, T | 1 |
| Yamaguchi, K | 1 |
| Abe, K | 1 |
| Nakayama, H | 1 |
| Aoki, N | 1 |
| Nishimura, S | 1 |
| Mizogami, H | 1 |
| Majima, H | 1 |
| Aoki, H | 1 |
| Sugenoya, H | 1 |
| Shirai, O | 1 |
| Toyoda, B | 1 |
| Sugihara, S | 1 |
| Ohganè, T | 1 |
| Niwa, M | 1 |
| Kure, M | 1 |
| Akimoto, M | 1 |
| Sawano, A | 1 |
| Iwasaki, H | 1 |
| Nakajima, Y | 1 |
| Matano, S | 1 |
| Kasai, M | 1 |
| Yamamura, M | 1 |
| Seiro, T | 1 |
| Miyauchi, S | 1 |
| Fujii, S | 1 |
| Futatsuki, K | 1 |
| Komita, T | 1 |
| Kamano, T | 1 |
| Taniya, T | 1 |
| Tajiri, K | 1 |
| Kitabayashi, K | 1 |
| Koshino, Y | 1 |
| Nonomura, A | 1 |
| Mabuchi, H | 1 |
| Ota, K | 1 |
| Ogasahara, K | 1 |
| Takeda, R | 1 |
| Nishizawa, F | 1 |
| Yoshimura, T | 1 |
| Takahashi, J | 1 |
| Kohno, Y | 1 |
| Bada, K | 1 |
| Ohbayashi, M | 1 |
| Imajo, K | 1 |
| Ozeki, H | 1 |
| Nagamine, D | 1 |
| Berté, E | 1 |
| Smith, TL | 1 |
| Meguro, F | 1 |
| Miyake, Y | 1 |
| Arai, Y | 1 |
| Kido, C | 1 |
| Endo, T | 1 |
| Ozawa, H | 1 |
| Motoki, R | 1 |
| Peek, U | 1 |
| Yasumura, T | 1 |
| Honjo, H | 1 |
| Okada, H | 1 |
| Kitamura, M | 1 |
| Takahashi, N | 1 |
| Yoshida, A | 1 |
| Noda, H | 1 |
| Kitamura, O | 1 |
| Sasaki, Y | 1 |
| Yasue, M | 1 |
| Ishijima, B | 1 |
| Sato, J | 1 |
| Mizutani, T | 1 |
| Morimatsu, Y | 1 |
| Eckhardt, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study[NCT04260269] | 200 participants (Anticipated) | Observational | 2018-06-01 | Enrolling by invitation | |||
| Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Docetaxel and S-1 in Breast Cancer[NCT00994968] | Phase 2 | 49 participants (Anticipated) | Interventional | 2009-07-31 | Recruiting | ||
| Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction[NCT03519074] | Phase 2 | 48 participants (Anticipated) | Interventional | 2016-07-22 | Recruiting | ||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| A Randomized Controlled Study of Postoperative Adjuvant Therapy of UFT Compared With CMF in High-risk Women With Axillary Node-negative Breast Cancer (NSAS-BC)[NCT00152191] | Phase 3 | 1,300 participants (Anticipated) | Interventional | 1996-10-31 | Completed | ||
| The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)[NCT00152178] | Phase 3 | 680 participants (Anticipated) | Interventional | 1996-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for tegafur and Breast Cancer
| Article | Year |
|---|---|
Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2021 |
Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical T | 2013 |
Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 2010 |
[Postoperative adjuvant chemotherapy for lung, gastric, colorectal and breast cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; | 2010 |
[Recent advance in adjuvant therapy for breast cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2002 |
Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast | 2003 |
[Clinical benefit of S-1 in metastatic breast cancer].
Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, | 2006 |
UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Colonic Ne | 2007 |
["State of the art" of adjuvant chemo-endocrine therapy for breast cancer in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical T | 1994 |
[Fundamental studies on the surgical adjuvant chemotherapy to support the clinical efficacies].
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast N | 1997 |
[Benefits of adjuvant chemotherapy for breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; | 1997 |
UFT: biochemical modulation for 5-fluorouracil (5-FU).
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as | 1997 |
Oral 5-FU analogues in the treatment of breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 1998 |
Fluoropyrimidines: a critical evaluation.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neopla | 1999 |
Epirubicin, cyclophosphamide, and UFT plus oral calcium folinate in advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1999 |
[S-1 for treatment of breast cancers].
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clini | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
UFT in the treatment of colorectal and breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2001 |
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2001 |
[Two cases of tubular adenoma of the breast].
Topics: Adenoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality | 1990 |
Potentiation of antimetabolite action by alkylating agents.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brea | 1985 |
92 trials available for tegafur and Breast Cancer
| Article | Year |
|---|---|
Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Combinations; D | 2021 |
Response Shift-Adjusted Treatment Effect on Health-Related Quality of Life in a Randomized Controlled Trial of Taxane Versus S-1 for Metastatic Breast Cancer: Structural Equation Modeling.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Combinations; Female; Humans; Latent Clas | 2020 |
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor | 2021 |
Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Drug Combinations; Female; Health Status; Humans; Jap | 2018 |
Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Drug Combinations; Female; Fl | 2018 |
Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Comb | 2018 |
Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2018 |
Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2019 |
Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients.
Topics: 4-Butyrolactone; Administration, Oral; Adult; Aged; Antigens, CD34; Antimetabolites, Antineoplastic; | 2014 |
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 2015 |
[Phase I study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 2013 |
S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel | 2013 |
Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Chemotherapy, | 2014 |
A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 2015 |
Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Admini | 2015 |
Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Deoxycytidine; | 2015 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease | 2016 |
Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial.
Topics: Adult; Aged; Breast Neoplasms; Drug Combinations; Female; Health Status; Humans; Middle Aged; Oxonic | 2017 |
A Phase II Study of Adjuvant Chemotherapy of Tegafur-Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2016 |
Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy | 2009 |
Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2009 |
[Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2009 |
Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial).
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemothera | 2010 |
A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 2010 |
A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2010 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Ne | 2010 |
Efficacy and safety of S-1 in patients with metastatic breast cancer: retrospective review in a single institution.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Drug Combinations; F | 2010 |
Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 2011 |
Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000-02 phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2011 |
Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
A phase I study of UFT-oral vinorelbine in metastatic breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female | 2011 |
Ten-year results of a randomized trial on adjuvant chemo-endocrine therapy with tamoxifen for stage II breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasm | 2003 |
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2003 |
Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2003 |
[A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Breast Neoplasms; Diarrhea; Drug Administrat | 2004 |
[Clinical usefulness of UFT and cyclophosphamide as salvage chemotherapy for patients with metastatic breast cancer].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinati | 2004 |
A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Combinations; Female; Humans; | 2005 |
Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2005 |
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set
Topics: Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Ne | 2006 |
Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cycloph | 2007 |
Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Dru | 2007 |
[Comparative study on two different types of tegafur for recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Delayed-Action Preparations; Drug Eva | 1984 |
A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1984 |
[A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1984 |
[Clinical trial of UFT against disseminated breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 1984 |
Tamoxifen alone versus tamoxifen plus 1-(2-tetrahydrofuryl)-5-fluorouracil in the treatment of advanced breast cancer: a sequential trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Adminis | 1981 |
Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1995 |
[Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1994 |
A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Meth | 1994 |
A cooperative randomized controlled study of adjuvant chemoendocrine therapy for breast cancer in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1994 |
Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 1994 |
[A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1993 |
Phase II trial of UFT activity in pretreated breast cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; A | 1993 |
Oral tegafur in the treatment of metastatic breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Blood Cell Count; Bone Neoplasms; Breast Neoplasms; Female; Human | 1993 |
A randomized trial comparing ftorafur alone with ftorafur plus tamoxifen in postoperative adjuvant therapy for breast cancer. Kinki Area Research Group for Postoperative Adjuvant Therapy for Breast Cancer.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Female; Humans; Middle Aged; Su | 1996 |
Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Can
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast | 1996 |
[Neoadjuvant therapy followed by administration of UFT for breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1996 |
A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1997 |
Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 1997 |
UFT in combination as adjuvant therapy for breast cancer. Grupo Oncologico de Sevilla Seville, Spain.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1997 |
Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast | 1998 |
Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral UFT (uracil/tegafur) versus six-cycle CMF (cyclophosphamide/methotrexate/5-fluorouracil) in high-risk node-negative breast cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 1998 |
[An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Administrati | 1998 |
Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral uracil/tegafur versus 6-cycle cyclophosphamide/methotrexate/5-fluorouracil in high-risk node-negative breast cancer patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineo | 1998 |
[A study on the efficacy of combination chemoendocrine therapy consisting of cyclophosphamide, adriamycin, UFT, and tamoxifen for advanced or recurrent breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylati | 1999 |
Paclitaxel, UFT, and calcium folinate in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Therapy, Combina | 1999 |
Paclitaxel and UFT plus oral calcium folinate in pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 1999 |
UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Adminis | 1999 |
UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Di | 1999 |
UFT plus oral calcium folinate/vinorelbine for advanced breast cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1999 |
Uracil/tegafur plus oral calcium folinate in advanced breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug T | 1999 |
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Drug Combinati | 1999 |
Dose-intense salvage therapy after neoadjuvant chemotherapy: feasibility and preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, | 1999 |
Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1999 |
[Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer: Tochigi Prefectural Study Group for Post-Breast Cancer Adjuvant Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2000 |
A phase I study. UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic | 2000 |
UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
UFT/leucovorin plus vinorelbine combination for advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2000 |
Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Hematopoietic Stem Ce | 2000 |
Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chem | 1992 |
The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy | 1992 |
Appraisal of adjuvant chemoendocrine therapy with tamoxifen plus tegafur in patients with breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Staging | 1991 |
[Clinical results of UFT granule of enteric coating (UFT E granule). Osaka UFT E Granule Study Group].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 1990 |
[A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1989 |
[Cooperative study of postoperative long-term adjuvant therapy of breast cancer. First study of a series--comparative study between postoperative tegafur administration and no adjuvant chemotherapy].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Axilla; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltr | 1988 |
[Tamoxifen plus tegafur plus low-dose adriamycin in the treatment of advanced breast cancer in an outpatient basis].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bre | 1987 |
Bilateral primary breast cancer in patients treated with adjuvant therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1988 |
[Cooperative research on post-operative adjuvant therapy of breast cancer. Tohoku Society of Adjuvant Chemo-endocrine Therapy of Breast Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Mitomycin; Mitomyc | 1988 |
[Preliminary report of adjuvant chemo-endocrine therapy for breast cancer].
Topics: Adult; Anorexia; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Combined Modality Therapy | 1985 |
[Clinical studies on chemo-immunotherapy for advanced and recurrent carcinoma of the breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dru | 1985 |
191 other studies available for tegafur and Breast Cancer
| Article | Year |
|---|---|
Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cycloph | 2019 |
[A Case of Metaplastic Squamous Cell Carcinoma of the Breast Successfully Treated with S-1].
Topics: Antimetabolites, Antineoplastic; Axilla; Biopsy, Large-Core Needle; Breast Neoplasms; Carcinoma, Squ | 2019 |
Pilot Study of Irinotecan and S-1 (IRIS) for Advanced and Metastatic Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival | 2020 |
Skin grafting utilizing a skin of lateral thoracic area for chest wall reconstruction in patient who underwent mastectomy for locally advanced breast cancer.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Axilla; Bi | 2021 |
[A Case of Lung Metastasis of the Breast Cancer with a Remarkable Response to Stereotactic Body Radiation Therapy(SBRT)].
Topics: Aged; Breast Neoplasms; Female; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Radiosurgery; Te | 2020 |
A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; D | 2021 |
Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinations; Female; Humans; M | 2021 |
Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
Topics: Administration, Oral; Aged; Breast Neoplasms; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Co | 2017 |
The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compound | 2017 |
Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as | 2017 |
[A Case of Stage IV Breast Cancer with Extensive Metastasis Successfully Treated with S-1 plus Anastrozole Therapy].
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Drug Co | 2017 |
Clinical efficacy and safety of S-1 monotherapy in the treatment of advanced breast cancer in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Drug Combinations; Female; Fl | 2018 |
[Analysis of Five Days of Administration of S-1 Followed by a Two-Day Rest in Patients with Metastatic Breast Cancer].
Topics: Adult; Aged; Breast Neoplasms; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Prospect | 2019 |
Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Br | 2019 |
[A case of recurrent breast cancer with multiple bone metastasis successfully treated with S-1 and zoledronic acid therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphona | 2013 |
Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2014 |
[Two cases of multiple liver metastases breast cancer successfully treated with combination chemotherapy by S-1, vinorelbine and medroxyprogesterone].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Female; | 2013 |
[A case of recurrent breast cancer with liver metastases showing good response to combination therapy with S-1 plus trastuzumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2013 |
[A case of advanced breast carcinoma effectively treated postoperatively with tegafur-uracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Hu | 2013 |
Prospective cohort study: whether or not patients benefit from participation itself in randomized-controlled trials (SELECT BC ECO).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Drug Combinati | 2014 |
[A case of squamous cell carcinoma of the nipple skin successfully treated with S-1 alone].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Carcinoma, Squamous Cell; | 2014 |
[Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer - an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 2014 |
Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer: a single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 2014 |
[Long-term control of stage IV breast and gastric cancer with combination therapy of S-1 and paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Drug Co | 2014 |
Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
Topics: Adult; Aged; Anthracyclines; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Combinations; Drug-Relat | 2015 |
[Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Drug Combinati | 2015 |
Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease | 2015 |
S-1 versus taxanes for HER2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans | 2016 |
[A Case of Peritoneal Metastasis of Breast Cancer Diagnosed by Laparoscopic-Assisted Right Hemicolectomy].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2015 |
[A Case of Primary Acinic Cell Carcinoma(ACC)of the Breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Acinar Cell; Chemothera | 2016 |
[Marked efficacy of S-1 against hepatic metastasis of multiple drug-resistant breast cancer--a report of 2 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Comb | 2008 |
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Bone Neoplasms; Bre | 2009 |
[A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; | 2008 |
[A case of recurrent breast carcinoma metastasis successfully treated with S-1 and zoledronic acid therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Diphospho | 2009 |
[A patient with multiple skin metastases from breast cancer responding to S-1 effectively under treatment with trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
[Nineteen years postoperatively, anastrozole, UFT and cyclophosphamide combination therapy remained effective against recurrent hormone responsive breast cancer with intraabdominal lymphnode, pleural, skin and bone metastases in old age following sixteen-
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2009 |
[A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2009 |
UFT plus oral folinic acid with alternating oral and intravenous vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Topics: Administration, Oral; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2009 |
[A case of bilateral breast cancer and metastatic gastric cancer with peritonitis carcinomatosa successfully treated with a combination therapy of S-1 and paclitaxel].
Topics: Adenocarcinoma, Scirrhous; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antin | 2009 |
[A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined C | 2009 |
[Three cases of metastatic breast cancer effectively treated with S-1 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Comb | 2010 |
[A case of breast cancer with multiple hepatic metastasis successfully treated with S-1/PTX and S-1 chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Female; Humans; | 2010 |
[A case of anthracycline- and taxane-resistant recurrent advanced breast cancer successfully treated with S-1 monotherapy].
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinations; Drug Resistanc | 2010 |
[Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid].
Topics: Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonate | 2010 |
[A case of luminal B recurrent breast cancer with liver and lymph node metastases successfully treated with combination therapy of S-1 plus trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
[A case of interstitial pneumonitis induced by S-1].
Topics: Aged, 80 and over; Breast Neoplasms; Drug Combinations; Female; Humans; Lung Diseases, Interstitial; | 2010 |
Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Blotting | 2011 |
Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Surv | 2010 |
[A case of multi-drug resistant breast cancer with liver metastasis treated effectively by S-1 monotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Combinations; Dru | 2010 |
[A case of capecitabine-resistant recurrent breast cancer found to be responsive to S-1].
Topics: Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; | 2010 |
[A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; An | 2010 |
[Effective chemotherapy with S-1 alone in a patient with lung metastases of breast cancer].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinations; Female; Humans; Lung Neoplasms | 2011 |
[A case of possible retroperitoneal metastasis of breast cancer successfully treated with oral S-1 and cyclophosphamide therapy after TC therapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Mod | 2011 |
[A patient with of metastatic breast cancer with a well-controlled quality of life using S-1 therapy as first-line chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Drug Combinations; Female; | 2011 |
[A successful case treated with S-1 and zoledronic acid for multiple bone metastasis of breast cancer].
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms | 2011 |
[A case of multiple metastases breast cancer controlled using S-1 as third-line chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Drug Combinations; Female; | 2011 |
Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine | 2011 |
[A case of breast cancer with postoperative metastasis to the supraclavicular lymph nodes-recurrence-free survival achieved by surgical excision following chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy, Needle; Breast Neoplasms; Clavicle; Combine | 2011 |
[Chemotherapy of a 2-week S-1 administration followed by 1-week rest for advanced and metastatic breast cancer].
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Disease Progression; Drug Combinations; Female; Humans; M | 2011 |
[Three cases effectively treated with S-1 therapy for liver metastasis of breast cancer in long term].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinations; Female; Humans; Liver Ne | 2011 |
Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer?
Topics: Aged; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combi | 2011 |
[A case of repeated bone metastases of breast carcinoma successfully treated by S-1 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Drug Combinations; Female; Humans | 2011 |
[A resected case of complete response after treatment with S-1 for recurrent squamous cell carcinoma component of the breast].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Squamous Cell; Combined Modality | 2012 |
[A case of advanced breast carcinoma treated with topical S-1 plus letrozole].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Drug Combinations; Female; | 2012 |
[Oral chemotherapy for advanced breast cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine | 2012 |
Oral ftorafur plus intramuscular thiotepa as adjuvant chemotherapy in patients with breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy | 2002 |
NICE recommends new treatment for breast and bowel cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2003 |
[A case of recurrent breast cancer with lung metastasis and overexpression of HER2 that responded to UFT and cyclophosphamide combination therapy after sequential treatments with epirubicin, taxanes, and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2003 |
[Simultaneous detection of both non-Hodgkin's lymphoma cells and breast cancer cells in pleural effusion--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 2003 |
A case of prurigo-type drug eruptions due to UFT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Drug Eruptions; Fe | 2003 |
[A case of liver metastases of breast cancer successfully treated by combination chemotherapy using hepatic arterial infusion of docetaxel and systemic administration of trastuzumab].
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2004 |
Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disea | 2004 |
[A case of anthracycline and taxane-resistant breast cancer with life-thereatening multiple liver metastases responding to oral combination chemotherapy by UFT, cyclophosphamide and medroxyprogesterone acetate].
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Anthracyclines; Antineoplastic Combined Chemotherap | 2005 |
[Effective salvage chemotherapy with S-1 alone in a patient with lung metastasis of breast cancer].
Topics: Administration, Oral; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Rin | 2005 |
[A case of liver metastasis successfully treated with S-1 monotherapy in the patient with recurrent breast cancer].
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ri | 2006 |
[Two patients effectively treated with S-1 therapy for liver metastasis of breast cancer resistant to other anticancer drugs].
Topics: Administration, Oral; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Rin | 2006 |
[Successful monotherapy with S-1 in three cases of recurrent/advanced breast cancer non-responsive to anthracycline and taxane anticancer drugs].
Topics: Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Brid | 2006 |
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cycloph | 2006 |
Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dihydrouracil Dehydrogena | 2006 |
S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplas | 2006 |
[A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
[A case of advanced breast cancer with meningeal carcinomas and orbital metastasis successfully treated with multi-disciplinary therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Carcinoma, Ductal; Comb | 2006 |
[A resected case of squamous cell carcinoma of the breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamous Cell; C | 2007 |
[A case of breast metastasis of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Signet Ring Cell; Cispl | 2007 |
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine | 2007 |
[A patient with pulmonary metastasis from breast cancer after surgery who responded to S-1].
Topics: Adenocarcinoma; Antigens, Tumor-Associated, Carbohydrate; Antimetabolites, Antineoplastic; Biomarker | 2007 |
Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dihydrouracil Dehydrogenase (NADP) | 2007 |
[A case of advanced breast cancer successfully treated with multi-disciplinary therapy and S-1 administration].
Topics: Biopsy, Needle; Breast Neoplasms; Drug Combinations; Female; Humans; Magnetic Resonance Imaging; Mid | 2007 |
Clinical efficacy of S-1 in pretreated metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms | 2008 |
[Effects of 5'-deoxy-5-fluorouridine on human gastrointestinal and breast cancers xenografted to nude mice].
Topics: Adenocarcinoma; Administration, Oral; Animals; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Femal | 1984 |
[Clinical study on preoperative chemotherapy of primary breast cancer. 2--A comparative study of CPA + FT-207 (5-FUDS) and CPA + FT-207 (5-FUDS) + MMC].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; | 1983 |
[Evaluation of chemotherapy of breast cancer (2). Clinical evaluation of the blood and tissue concentrations of FT-207 following intrarectal administration].
Topics: Breast; Breast Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes; Suppositories; Tegafur | 1983 |
[UFT concentration in various tissues from cancer patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1983 |
[Analysis of factors affecting clinical cancer chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Fluorouraci | 1983 |
[Clinical analysis on side effects of long-term oral administration of futraful to out-patients].
Topics: Administration, Oral; Alanine Transaminase; Aspartate Aminotransferases; Blood Proteins; Breast Neop | 1983 |
[Cooperative phase II study of spansule tegafur (SF-SP)].
Topics: Administration, Oral; Aged; Breast Neoplasms; Capsules; Colonic Neoplasms; Delayed-Action Preparatio | 1984 |
Phase I-II studies of oral tegafur (ftorafur).
Topics: Administration, Oral; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship, | 1983 |
[Experimental chemotherapy of human gastrointestinal and breast cancers in nude mice and its correlation to clinical effect].
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 1984 |
[Study on the concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after administration of FT-207 suppositories].
Topics: Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Mal | 1984 |
[A case of recurrent breast cancer responding to long-term administration of tamoxifen].
Topics: Adult; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; T | 1984 |
Recent advances in chemotherapy for advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Infusions, Intra | 1981 |
[Chemo-endocrine therapy for advanced breast cancer--a combined treatment with tamoxifen and FT 207-- (author's transl)].
Topics: Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Tamoxifen; Tegafur | 1981 |
[ACF combination consisting of adriamycin, cyclophosphamide and oral futraful for recurrent advanced breast cancer (author's transl)].
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Flu | 1981 |
[Chemotherapy of advanced breast cancer--actual results ].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, C | 1982 |
[Significance of chemo-endocrine therapy in advanced breast cancer--a combined administration of tamoxifen, tegafur, and cyclophosphamide].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Drug Therap | 1982 |
[Clinical study of preoperative chemotherapy of primary breast cancer. 1. Efficacy of a combined use of CPA (endoxan) and FT-207 (or 5-FU dry syrup)].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; F | 1982 |
[Concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combin | 1982 |
[A case of interstitial pneumonia due to UFT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lung Diseases, Int | 1995 |
[Antiproliferative and antimetastatic effects of UFT on MKL-4 human breast cancer cells transplanted into nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Humans; Ly | 1995 |
[A case of bilateral multiple lung metastases from breast cancer successfully treated with carboplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Femal | 1995 |
[Improvement of clinical symptoms by UFT and TAM and a case of bone metastasis from breast carcinoma during pregnancy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Female; Hum | 1994 |
[A case of peritoneal metastasis of breast cancer successfully treated by multidisciplinary therapy with hyperthermia therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1994 |
[A case of breast cancer with thrombosis during treatment of lung metastasis].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug A | 1993 |
Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brea | 1995 |
[Evaluation of subrenal capsule assay (SRC) for clinical cancers].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy | 1996 |
Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support.
Topics: Adult; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea | 1997 |
[Prognostic effect of PyNPase (pyrimidine nucleoside phosphorylase) activity in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 1998 |
[Results of combination therapy of UFT-E with low-dose CDDP for patients with advanced recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 1998 |
Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice.
Topics: Animals; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; | 1997 |
[Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report].
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1999 |
Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brea | 1999 |
Patients' concerns about clinical trials in Japan.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1999 |
[UFT-E granule compliance in postoperative adjuvant chemotherapy].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1999 |
[A patient with hepatic metastasis of breast cancer successfully treated with combined chemoendocrine therapy using epirubicin, tegafur and tamoxifen].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Ad | 1999 |
[Improved QOL with cancer chemotherapy in two patients with breast cancer suffering form carcinomatous pleurisy and carcinomatous peritonitis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubic | 2000 |
[A case of postoperative lung and pleural recurrence after 20 years in a breast cancer patient with marked response to orally administered UFT and cyclophosphamide].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cycloph | 2000 |
[Antitumor activity of UFT and docetaxel on human breast carcinoma xenografts].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans | 2000 |
[Three cases of metastatic breast cancer, resistant to pre-chemo and/or endocrine therapy, markedly improved with UFT and cyclophosphamide oral combination therapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplas | 2000 |
[A case of pulmonary metastases of breast cancer responding remarkably to combined chemotherapy with 5-fluorouracil and low-dose cisplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Ad | 2000 |
[A case of breast cancer with multiple metastases successfully treated by medroxyprogesterone acetate with intermittent intra-arterial infusion low-dose chemotherapy to hepatic metastasis].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre | 2000 |
Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cachexia; Docetaxel; Drug Interactions; | 2001 |
[A case of breast cancer with multiple metastases effectively treated with long-term administration of docetaxel, aclarubicin and UFT].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast | 2001 |
[Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung].
Topics: Aminoacridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea | 2002 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
[The antitumor activity of DPD inhibitory-fluoropyrimidine (DIF) and non-DIF alone or in combination with paclitaxel against orthotopically implanted human breast cancer].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Di | 2002 |
[Effectiveness of ftorafur and hexamethylmelamine in advanced breast cancer].
Topics: Adult; Altretamine; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leuko | 1978 |
[Ftorafur concentration in the blood and urine of oncological patients].
Topics: Biopharmaceutics; Biotransformation; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Flu | 1977 |
[Use of ftorafur in disseminated breast cancer].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Female; Fluorouracil; Humans; Middle | 1978 |
Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Body Weight; Breast Neoplasms; Central Nervous Syst | 1979 |
Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer.
Topics: BCG Vaccine; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin; Drug Therapy; Female; Fluo | 1979 |
[A case report of bone metastasis diagnosed by MRI and effectively treated with UFT after breast conserving therapy for breast cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast N | 1992 |
[A case report of multiple bone metastases of breast carcinoma effectively treated with mild chemo-endocrine therapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neoplasms | 1992 |
Evaluation of prognostic factors for 233 patients with recurrent advanced breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1991 |
[The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Femal | 1991 |
[Experimental combined chemo- and endocrine therapy with UFT and tamoxifen in human breast carcinoma xenografts serially transplanted into nude mice].
Topics: Animals; Breast Neoplasms; Combined Modality Therapy; Female; Mice; Mice, Inbred BALB C; Mice, Nude; | 1990 |
[Relationship between antitumor activity and the inhibition of thymidylate synthase after oral administration of UFT in nude mice bearing human tumor].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cel | 1990 |
[Experimental study of the effect of combined treatment of UFT with CDDP on human solid tumor-xenografts in nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cisplatin; | 1990 |
[UFT-MT therapy in advanced or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl | 1990 |
[A case of brain metastasis from breast cancer responding to chemoendocrine therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, | 1990 |
[A case of local recurrent breast cancer with complete response to combination of systemic chemotherapy and topical use of adriamycin ointment].
Topics: Administration, Topical; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin | 1990 |
[A case of bone and lung metastasis of breast cancer successfully treated with radiotherapy, chemotherapy and endocrine therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1990 |
Impact of initial therapy on survival in recurrent breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Tamoxifen; T | 1989 |
[A case of breast cancer with multiple bone metastases effectively treated with UFT and tamoxifen].
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplas | 1989 |
[Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Adm | 1989 |
[Changes in lymphocyte subsets with post-operative chemotherapy in breast carcinoma--a study of using two color analysis].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined M | 1989 |
[Analysis of prognostic factors in patients with locally advanced breast cancer treated with intra-arterial infusion chemotherapy as an induction therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1989 |
The discrepancy between immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine therapy.
Topics: Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; D | 1989 |
[The serum and tissue concentration of FT-207, 5'-DFUR and 5-FU in patients with breast cancer by preoperative administration of UFT and 5'-DFUR].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Floxuridine; Fluorouracil; | 1989 |
[Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Drug Evaluation; Drug Resistance; Drug Therapy, Combinat | 1989 |
[Mammary gland carcinoma treated by large-dose medroxyprogesterone acetate of which pulmonary metastases disappeared and a selection of hormone, chemoimmunological treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Thera | 1989 |
[A study of complete responders in cases of metastatic breast cancer treated with combination chemotherapy].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 1989 |
[A carcinoma of the right breast arising after a mastectomy in primary malignant lymphoma of the left breast].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combine | 1989 |
[A comparative study of 5'-DFUR and tegafur in recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Capsules; Diar | 1985 |
[Hormone therapy of breast cancer-its role in the treatment of breast cancer].
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Medroxyprogesterone; | 1985 |
[Combination chemotherapy with 3 or 4 drugs on human breast and gastrointestinal cancer xenografts in nude mice (II)].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1987 |
[Bone metastasis in advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Calcitonin; Cyclop | 1987 |
[Combination chemotherapy using low-dose epirubicin and vindesine in patients with metastatic breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1988 |
Reversible leukoencephalopathy caused by 5-fluorouracil derivatives, presenting as akinetic mutism.
Topics: Anal Gland Neoplasms; Animals; Breast Neoplasms; Carcinoma; Female; Fluorouracil; Humans; Leukoencep | 1986 |
[Study of chemotherapy in the field of internal medicine--clinical experience with SF-SP].
Topics: Administration, Oral; Aged; Breast Neoplasms; Colonic Neoplasms; Delayed-Action Preparations; Drug A | 1986 |
[Anosmia or hyposmia after long-term oral administration of tegafur--improved anosmia].
Topics: Aged; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Olfaction D | 1986 |
[The concentration in the tissue and antitumor effect of anticancer drug--assessment of breast cancer with UFT or FT-207].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Drug Administration Schedu | 1986 |
[Complete remission in a case of concurrent breast and thyroid cancers with metastatic spinal paralysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Humans; Middle | 1986 |
[Prevention of cancer chemotherapeutic agent-induced toxicity in postoperative breast cancer patients with glycyrrhizin (SNMC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Glycyrrhetini | 1986 |
[Thymidylate synthase inhibition in malignant tumors after oral administration of UFT].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1986 |
[Clinical results of treatment with the UFT fine granule preparation under cooperative study. Tokyo Cancer Chemotherapy Cooperative Study Group].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast | 1987 |
[A case report of hyperlipemia with giant fatty liver during adjuvant endocrine therapy by tamoxifen].
Topics: Adenocarcinoma; Adult; Breast Neoplasms; Fatty Liver; Female; Humans; Hyperlipidemias; Lung Neoplasm | 1987 |
[Report on nationwide pooled data and cohort investigation in UFT phase II study].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Sche | 1987 |
[Clinical results of UFT fine granule therapy by cooperative study. Osaka UFT Granulation Study Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capsules; Drug Admini | 1987 |
[A case of breast cancer with pleural metastasis responding to administration of intrapleural adriamycin and systemic chemotherapy with FEMP].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1987 |
[Adriamycin, cyclophosphamide, ftorafur and tamoxifen (ACFT) in patients with advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1988 |
[ACFT therapy using adriamycin, cyclophosphamide, tegafur and tamoxifen against progressive breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1988 |
[Changes in CT findings in patients with liver metastases of breast cancer during effective intra-arterial infusion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Humans; Infusion Pump | 1988 |
[Evaluation of the ATF (low dose adriamycin + tamoxifen + tegafur) therapy as adjuvant chemotherapy of breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1988 |
[Inflammatory breast carcinoma--possibilities and results of surgical treatment and adjuvant chemotherapy, especially when done preoperatively].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxor | 1988 |
[Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy].
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamid | 1988 |
[Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 1988 |
[Preoperative chemotherapy for advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxor | 1985 |
[5-FU concentration in the tissues (tumor and lymph node) of breast cancer patients given preoperative administration of UFT and FT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Female; Fluorouracil; Huma | 1985 |
[A case of advanced male breast cancer treated effectively with estrogen].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Combined Modality The | 1985 |
[A case of long-term survival of liver metastasis of breast cancer successfully treated with chemotherapy and endocrine therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cy | 1985 |
[A case of toxic leucoencephalopathy induced by 5FU derivatives].
Topics: Antineoplastic Agents; Brain; Brain Diseases; Breast Neoplasms; Female; Fluorouracil; Humans; Middle | 1985 |